                         SEQUENCE LISTING

<110>  SANOFI
 
<120>  Anti-CD3 antibodies, anti-CD123 antibodies and bispecific 
       antibodies specifically binding to CD3 and/or CD123

<130>  FR2014/021-WO-PCT

<150>  EP15305077.8
<151>  2015-01-23

<160>  400   

<170>  PatentIn version 3.5

<210>  1
<211>  207
<212>  PRT
<213>  Homo sapiens

<400>  1

Met Gln Ser Gly Thr His Trp Arg Val Leu Gly Leu Cys Leu Leu Ser 
1               5                   10                  15      


Val Gly Val Trp Gly Gln Asp Gly Asn Glu Glu Met Gly Gly Ile Thr 
            20                  25                  30          


Gln Thr Pro Tyr Lys Val Ser Ile Ser Gly Thr Thr Val Ile Leu Thr 
        35                  40                  45              


Cys Pro Gln Tyr Pro Gly Ser Glu Ile Leu Trp Gln His Asn Asp Lys 
    50                  55                  60                  


Asn Ile Gly Gly Asp Glu Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp 
65                  70                  75                  80  


His Leu Ser Leu Lys Glu Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr 
                85                  90                  95      


Val Cys Tyr Pro Arg Gly Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu 
            100                 105                 110         


Tyr Leu Arg Ala Arg Val Cys Glu Asn Cys Met Glu Met Asp Val Met 
        115                 120                 125             


Ser Val Ala Thr Ile Val Ile Val Asp Ile Cys Ile Thr Gly Gly Leu 
    130                 135                 140                 


Leu Leu Leu Val Tyr Tyr Trp Ser Lys Asn Arg Lys Ala Lys Ala Lys 
145                 150                 155                 160 


Pro Val Thr Arg Gly Ala Gly Ala Gly Gly Arg Gln Arg Gly Gln Asn 
                165                 170                 175     


Lys Glu Arg Pro Pro Pro Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg 
            180                 185                 190         


Lys Gly Gln Arg Asp Leu Tyr Ser Gly Leu Asn Gln Arg Arg Ile 
        195                 200                 205         


<210>  2
<211>  198
<212>  PRT
<213>  Macaca fascicularis

<400>  2

Met Gln Ser Gly Thr Arg Trp Arg Val Leu Gly Leu Cys Leu Leu Ser 
1               5                   10                  15      


Ile Gly Val Trp Gly Gln Asp Gly Asn Glu Glu Met Gly Ser Ile Thr 
            20                  25                  30          


Gln Thr Pro Tyr Gln Val Ser Ile Ser Gly Thr Thr Val Ile Leu Thr 
        35                  40                  45              


Cys Ser Gln His Leu Gly Ser Glu Ala Gln Trp Gln His Asn Gly Lys 
    50                  55                  60                  


Asn Lys Glu Asp Ser Gly Asp Arg Leu Phe Leu Pro Glu Phe Ser Glu 
65                  70                  75                  80  


Met Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg Gly Ser Asn Pro 
                85                  90                  95      


Glu Asp Ala Ser His His Leu Tyr Leu Lys Ala Arg Val Cys Glu Asn 
            100                 105                 110         


Cys Met Glu Met Asp Val Met Ala Val Ala Thr Ile Val Ile Val Asp 
        115                 120                 125             


Ile Cys Ile Thr Leu Gly Leu Leu Leu Leu Val Tyr Tyr Trp Ser Lys 
    130                 135                 140                 


Asn Arg Lys Ala Lys Ala Lys Pro Val Thr Arg Gly Ala Gly Ala Gly 
145                 150                 155                 160 


Gly Arg Gln Arg Gly Gln Asn Lys Glu Arg Pro Pro Pro Val Pro Asn 
                165                 170                 175     


Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Gln Asp Leu Tyr Ser Gly 
            180                 185                 190         


Leu Asn Gln Arg Arg Ile 
        195             


<210>  3
<211>  340
<212>  PRT
<213>  Homo sapiens


<220>
<221>  DOMAIN
<222>  (1)..(104)
<223>  extracellular domain of human CD3 epsilon

<220>
<221>  MISC_FEATURE
<222>  (105)..(340)
<223>  His-tagged FC-Fusion

<400>  3

Asp Gly Asn Glu Glu Met Gly Gly Ile Thr Gln Thr Pro Tyr Lys Val 
1               5                   10                  15      


Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Pro Gln Tyr Pro Gly 
            20                  25                  30          


Ser Glu Ile Leu Trp Gln His Asn Asp Lys Asn Ile Gly Gly Asp Glu 
        35                  40                  45              


Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp His Leu Ser Leu Lys Glu 
    50                  55                  60                  


Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg Gly 
65                  70                  75                  80  


Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu Tyr Leu Arg Ala Arg Val 
                85                  90                  95      


Cys Glu Asn Cys Met Glu Met Asp Gly Ser Asp Lys Thr His Thr Cys 
            100                 105                 110         


Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 
        115                 120                 125             


Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 
    130                 135                 140                 


Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 
145                 150                 155                 160 


Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 
                165                 170                 175     


Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 
            180                 185                 190         


Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 
        195                 200                 205             


Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 
    210                 215                 220                 


Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 
225                 230                 235                 240 


Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 
                245                 250                 255     


Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 
            260                 265                 270         


Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 
        275                 280                 285             


Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 
    290                 295                 300                 


Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 
305                 310                 315                 320 


His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly His His His His 
                325                 330                 335     


His His His His 
            340 


<210>  4
<211>  333
<212>  PRT
<213>  Macaca fascicularis


<220>
<221>  Domain
<222>  (1)..(95)
<223>  extracellular domain of Macaca fascicularis CD3epsilon protein

<220>
<221>  MISC_FEATURE
<222>  (96)..(333)
<223>  Fc fusion

<400>  4

Asp Gly Asn Glu Glu Met Gly Ser Ile Thr Gln Thr Pro Tyr Gln Val 
1               5                   10                  15      


Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Ser Gln His Leu Gly 
            20                  25                  30          


Ser Glu Val Gln Trp Gln His Asn Gly Lys Asn Lys Glu Asp Ser Gly 
        35                  40                  45              


Asp Arg Leu Phe Leu Pro Glu Phe Ser Glu Met Glu Gln Ser Gly Tyr 
    50                  55                  60                  


Tyr Val Cys Tyr Pro Arg Gly Ser Asn Pro Glu Asp Ala Ser His His 
65                  70                  75                  80  


Leu Tyr Leu Lys Ala Arg Val Cys Glu Asn Cys Met Glu Met Asp Gly 
                85                  90                  95      


Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 
            100                 105                 110         


Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 
        115                 120                 125             


Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 
    130                 135                 140                 


His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 
145                 150                 155                 160 


Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 
                165                 170                 175     


Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 
            180                 185                 190         


Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 
        195                 200                 205             


Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 
    210                 215                 220                 


Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 
225                 230                 235                 240 


Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 
                245                 250                 255     


Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 
            260                 265                 270         


Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 
        275                 280                 285             


Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 
    290                 295                 300                 


Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 
305                 310                 315                 320 


Ser Pro Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys 
                325                 330             


<210>  5
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "20G6-F3" anti-CD3 antibody

<400>  5

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  6
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "20G6-F3" anti-CD3antibody

<400>  6

Gly Phe Thr Phe Thr Lys Ala Trp 
1               5               


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "20G6-F3" anti-CD3antibody

<400>  7

Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr 
1               5                   10  


<210>  8
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "20G6-F3" anti-CD3antibody

<400>  8

Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr 
1               5                   10          


<210>  9
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "20G6-F3" anti-CD3 antibody

<400>  9

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Asp Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  10
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called called "20G6-F3", "11D7-C3" , "13H2-C2" ,
       "13C1-F6", "1E6-C9, "10F4-C10", "18G9-H11", "12G3-E8", "5B1-G2", 
       "16F8-A7", "11F9-F8", "8C2-F7", "20E5-F10" and "3H6-D2" anti-CD3 
       antibodies

<400>  10

Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "20G6-F3", "4B4-D7" , "11H3-E5"  , 
       "13H2-C2", "13C1-F6", "10F4-C10", "4E7-C9", "11F3-B9", "12G3-E8",
       "5B1-G2", "6F4-D10", "16F8-A7", "20E5-F10" and "3H6-D2" anti-CD3 
       antibodies

<400>  11

Gly Gln Gly Thr Gln Tyr Pro Phe Thr 
1               5                   


<210>  12
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "4B4-D7" anti-CD3 antibody.

<400>  12

Glu Val Gln Leu Val Glu Thr Gly Gly Arg Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  13
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "20G6-F3", "4B4-D7" , "11H3-E5"  , 
       "13H2-C2", "13C1-F6", "10F4-C10", "4E7-C9", "11F3-B9", "12G3-E8",
       "5B1-G2", "16F8-A7", "20E5-F10" and "3H6-D2" anti-CD3 antibodies.

<400>  13

Gly Phe Thr Phe Ser Asn Ala Trp 
1               5               


<210>  14
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "4B4-D7" anti-CD3 antibody

<400>  14

Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr 
1               5                   10  


<210>  15
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "4B4-D7" anti-CD3 antibody.

<400>  15

Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr 
1               5                   10          


<210>  16
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "4B4-D7" anti-CD3 antibody

<400>  16

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Thr Ser 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  17
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "4B4-D7", "11H3-E5" and "11F3-B9" 
       anti-CD3 antibodies.

<400>  17

Gln Ser Leu Val His Asp Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  18
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "4E7-C9" anti-CD3 antibody

<400>  18

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Pro Lys Arg Ser 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Tyr Val His Tyr Gly Ile Gly Tyr Ala Met Asp Ala Trp 
            100                 105                 110         


Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120         


<210>  19
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "4E7-C9", "18F5-H10", "20E5-F10" and 
       "3H6-D2" anti-CD3 antibodies

<400>  19

Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr 
1               5                   10  


<210>  20
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "4E7-C9" anti-CD3 antibody

<400>  20

Arg Tyr Val His Tyr Gly Ile Gly Tyr Ala Met Asp Ala 
1               5                   10              


<210>  21
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "4E7-C9" anti-CD3 antibody

<400>  21

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  22
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "4E7-C9" anti-CD3 antibody

<400>  22

Gln Ser Leu Glu His Asn Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  23
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "18F5-H10" anti-CD3 antibody

<400>  23

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Thr Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Arg Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Tyr Val His Tyr Arg Phe Ala Tyr Ala Leu Asp Ala Trp 
            100                 105                 110         


Gly Arg Gly Thr Ser Val Ser Val Ser Ser 
        115                 120         


<210>  24
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "18F5-H10" anti-CD3 antibody

<400>  24

Gly Phe Thr Phe Thr Asn Ala Trp 
1               5               


<210>  25
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "18F5-H10" anti-CD3 antibody

<400>  25

Arg Tyr Val His Tyr Arg Phe Ala Tyr Ala Leu Asp Ala 
1               5                   10              


<210>  26
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "18F5-H10" anti-CD3 antibody

<400>  26

Asp Val Leu Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Thr 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr His Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  27
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "18F5-H10" anti-CD3 antibody

<400>  27

Gln Ser Leu Val His Thr Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "18F5-H10", "11D7-C3", "1E6-C9" and 
       "10E6-G6" anti-CD3 antibodies

<400>  28

Gly Gln Gly Thr His Tyr Pro Phe Thr 
1               5                   


<210>  29
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "12D2-E5" anti-CD3 antibody

<400>  29

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Tyr Ala Tyr 
            20                  25                  30          


Trp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Lys Lys Asp Gly Thr Thr Ile Asn Tyr Thr Pro Ser Leu 
    50                  55                  60                  


Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Gln Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Thr Lys Leu Gly Ser Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Glu Arg Asp Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Val 
            100                 105                 110         


Met Val Thr Val Ser Ser 
        115             


<210>  30
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "12D2-E5" anti-CD3 antibody

<400>  30

Gly Phe Asn Phe Tyr Ala Tyr Trp 
1               5               


<210>  31
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "12D2-E5" anti-CD3 antibody

<400>  31

Ile Lys Lys Asp Gly Thr Thr Ile 
1               5               


<210>  32
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "12D2-E5" and "3G5-E10" anti-CD3 antibody

<400>  32

Ala Arg Glu Glu Arg Asp Gly Tyr Phe Asp Tyr 
1               5                   10      


<210>  33
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "12D2-E5" anti-CD3 antibody.

<400>  33

Gln Phe Val Leu Thr Gln Pro Asn Ser Val Ser Thr Asn Leu Gly Ser 
1               5                   10                  15      


Thr Val Lys Leu Ser Cys Lys Arg Ser Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln His Glu Gly Arg Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn 
65                  70                  75                  80  


Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 


<210>  34
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "12D2-E5" anti-CD3 antibody

<400>  34

Thr Gly Asn Ile Gly Ser Asn Tyr 
1               5               


<210>  35
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "12D2-E5" anti-CD3 antibody

<400>  35

Gln Ser Tyr Ser Ser Gly Ile Val 
1               5               


<210>  36
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "11D7-C3" anti-CD3 antibody

<400>  36

Glu Val Gln Phe Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Thr Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Leu Tyr Tyr Gly Leu Ser Pro Ser Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  37
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "11D7-C3", "11H3-E5", "13H2-C2", 
       "13C1-F6", "1E6-C9", "10F4-C10", "18G9-H11", "11F3-B9", 
       "6F4-D10", "16F8-A7", "11F9-F8" and "20B5-F10" anti-CD3 
       antibodies

<400>  37

Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr 
1               5                   10  


<210>  38
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "11D7-C3" anti-CD3 antibody

<400>  38

Arg Gly Leu Tyr Tyr Gly Leu Ser Pro Ser Asp Tyr 
1               5                   10          


<210>  39
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "11D7-C3" anti-CD3 antibody.

<400>  39

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr His Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  40
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "11H3-E5" anti-CD3 antibody

<400>  40

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Tyr Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  41
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called called "11H3-E5" anti-CD3 antibody

<400>  41

Arg Gly Thr Tyr Tyr Ala Tyr Lys Pro Phe Asp Tyr 
1               5                   10          


<210>  42
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "11H3-E5" anti-CD3 antibody

<400>  42

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Thr Ser 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  43
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "13H2-C2" anti-CD3 antibody.

<400>  43

Glu Glu Glu Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Asp Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Asn Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Tyr Val His Tyr Gly Leu Ala Pro Met Asp Ala Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  44
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "13H2-C2" anti-CD3 antibody

<400>  44

Arg Tyr Val His Tyr Gly Leu Ala Pro Met Asp Ala 
1               5                   10          


<210>  45
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "13H2-C2" anti-CD3 antibody

<400>  45

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Ala Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ile Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Phe Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  46
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "13C1-F6" and "11F9-F8" anti-CD3 antibodies

<400>  46

Glu Val Gln Leu Val Glu Thr Gly Gly Thr Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Thr Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Leu Asn Ser Leu Arg Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Gln Tyr Gly Tyr Asn Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  47
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of so-called "13C1-F6", "10E6-G6" and "11F9-F8" anti-CD3 
       antibodies

<400>  47

Arg Gly Thr Gln Tyr Gly Tyr Asn Pro Phe Asp Tyr 
1               5                   10          


<210>  48
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "13H2-C2" anti-CD3 antibody

<400>  48

Asp Val Val Met Thr Gln Ser Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Arg Ser Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Ile Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys 
            100                 105                 110         


<210>  49
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "18H11-F10" anti-CD3 antibody

<400>  49

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Asp Tyr 
            20                  25                  30          


Tyr Met Ala Trp Val Arg Gln Ala Pro Lys Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Ser Ile Ser Gly Ser Arg Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asn Asn Pro Gly Gly Trp Phe Val Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  50
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called  "18H11-F10" anti-CD3 antibody

<400>  50

Gly Phe Ile Phe Ser Asp Tyr Tyr 
1               5               


<210>  51
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called  "18H11-F10" anti-CD3 antibody

<400>  51

Ile Ser Ile Ser Gly Ser Arg Thr 
1               5               


<210>  52
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called  "18H11-F10" anti-CD3 antibody

<400>  52

Ala Thr Asn Asn Pro Gly Gly Trp Phe Val Tyr 
1               5                   10      


<210>  53
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "18H11-F10" anti-CD3 antibody

<400>  53

Asn Ile Gln Met Thr Gln Ser Pro Ser Leu Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Leu Ser Cys Lys Ala Gly Gln Asn Ile Asn Asn Asp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Leu Gly Glu Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asn Ala Asn Ser Leu Gln Thr Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln Tyr Ser Ser Gly Asp Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  54
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called  "18H11-F10" anti-CD3 antibody

<400>  54

Gln Asn Ile Asn Asn Asp 
1               5       


<210>  55
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "18H11-F10" anti-CD3 antibody

<400>  55

Gln Gln Tyr Ser Ser Gly Asp Thr 
1               5               


<210>  56
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "1E6-C9" anti-CD3 antibody

<400>  56

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Tyr Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Asp Lys Gln Leu Gln Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Gly Leu Leu Gly Leu Asp Ala Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  57
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "1E6-C9" anti-CD3 antibody

<400>  57

Gly Phe Thr Phe Ser Tyr Ala Trp 
1               5               


<210>  58
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "1E6-C9" anti-CD3 antibody

<400>  58

Arg Gly Val Tyr Tyr Gly Leu Leu Gly Leu Asp Ala 
1               5                   10          


<210>  59
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "1E6-C9" anti-CD3 antibody

<400>  59

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Arg Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Phe Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Ala Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr His Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  60
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "10F4-C10" anti-CD3 antibody

<400>  60

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Ile Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Ala Val Asn Tyr Gly Asn Tyr Pro Leu Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  61
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "10F4-C10" anti-CD3 antibody

<400>  61

Arg Ala Val Asn Tyr Gly Asn Tyr Pro Leu Asp Tyr 
1               5                   10          


<210>  62
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "10F4-C10" anti-CD3 antibody

<400>  62

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Cys Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  63
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "10E6-G6" anti-CD3 antibody

<400>  63

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Ser Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Val Thr Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Glu Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Gln Tyr Gly Tyr Asn Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  64
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "10E6-G6" anti-CD3 antibody

<400>  64

Gly Phe Thr Val Thr Asn Ala Trp 
1               5               


<210>  65
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "10E6-G6" anti-CD3 antibody

<400>  65

Ile Lys Ala Lys Ser Asn Asn Tyr Glu Thr 
1               5                   10  


<210>  66
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "10E6-G6" anti-CD3 antibody

<400>  66

Asp Val Val Met Thr Gln Ser Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Tyr Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Phe Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Ile Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr His Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  67
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "10E6-G6" anti-CD3 antibody

<400>  67

Gln Ser Leu Val His Asn Asn Gly Tyr Thr Tyr 
1               5                   10      


<210>  68
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "18G9-H11" anti-CD3 antibody

<400>  68

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Ile Gln Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Leu Tyr 
                85                  90                  95      


Tyr Cys Thr Trp Arg His Tyr Tyr Ser Ser His Thr Met Asp Ala Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  69
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "18G9-H11" anti-CD3 antibody

<400>  69

Thr Trp Arg His Tyr Tyr Ser Ser His Thr Met Asp Ala 
1               5                   10              


<210>  70
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "18G9-H11" anti-CD3 antibody

<400>  70

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Ala Pro Thr Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Ser Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  71
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "18G9-H11" anti-CD3 antibody

<400>  71

Gly Gln Gly Ser Gln Tyr Pro Phe Thr 
1               5                   


<210>  72
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "11F3-B9" anti-CD3 antibody

<400>  72

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Thr Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Tyr Val Asn Tyr Gly Leu Ala Pro Met Asp Val Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  73
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "11F3-B9" anti-CD3 antibody

<400>  73

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  74
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "12G3-E8" anti-CD3 antibody

<400>  74

Glu Val Arg Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Leu Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Lys Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ala Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Arg Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Gly Phe Ser Met Thr Pro Phe Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120             


<210>  75
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "18G9-H11" anti-CD3 antibody

<400>  75

Gly Phe Thr Phe Ser Leu Ala Trp 
1               5               


<210>  76
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "18G9-H11" anti-CD3 antibody

<400>  76

Ile Lys Asp Lys Ala Asn Asn Tyr Ala Thr 
1               5                   10  


<210>  77
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "18G9-H11" anti-CD3 antibody

<400>  77

Arg Gly Val Tyr Tyr Gly Phe Ser Met Thr Pro Phe Asp Tyr 
1               5                   10                  


<210>  78
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "12G3-E8" anti-CD3 antibody

<400>  78

Asp Val Ala Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  79
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "5B1-G2" anti-CD3 antibody

<400>  79

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Ser Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ala Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Gly Ser 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Leu Tyr Tyr Gly Leu Phe Pro Ser Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  80
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "5B1-G2" anti-CD3 antibody

<400>  80

Gly Phe Ser Phe Ser Asn Ala Trp 
1               5               


<210>  81
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "5B1-G2" anti-CD3 antibody

<400>  81

Arg Gly Leu Tyr Tyr Gly Leu Phe Pro Ser Asp Tyr 
1               5                   10          


<210>  82
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "5B1-G2" anti-CD3 antibody

<400>  82

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Leu Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Leu Glu Pro Asp Asp Leu Gly Ile Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  83
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  part of VH of the so-called "16F8-A7" anti-CD3 antibody

<400>  83

Val Glu Thr Gly Gly Asn Leu Val Gln Pro Gly Lys Ser Leu Lys Leu 
1               5                   10                  15      


Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala Trp Met His Trp 
            20                  25                  30          


Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val Ala Gln Ile Lys 
        35                  40                  45              


Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly 
    50                  55                  60                  


Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln 
65                  70                  75                  80  


Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Tyr 
                85                  90                  95      


Val Asn Tyr Gly Leu Ala Pro Met Asp Val Trp Gly Gln Gly Thr Ser 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  84
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "16F8-A7" and "11F3-B9" anti-CD3 
       antibodies

<400>  84

Arg Tyr Val Asn Tyr Gly Leu Ala Pro Met Asp Val 
1               5                   10          


<210>  85
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "16F8-A7" anti-CD3 antibody

<400>  85

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  86
<211>  171
<212>  PRT
<213>  Homo sapiens

<400>  86

Met Glu His Ser Thr Phe Leu Ser Gly Leu Val Leu Ala Thr Leu Leu 
1               5                   10                  15      


Ser Gln Val Ser Pro Phe Lys Ile Pro Ile Glu Glu Leu Glu Asp Arg 
            20                  25                  30          


Val Phe Val Asn Cys Asn Thr Ser Ile Thr Trp Val Glu Gly Thr Val 
        35                  40                  45              


Gly Thr Leu Leu Ser Asp Ile Thr Arg Leu Asp Leu Gly Lys Arg Ile 
    50                  55                  60                  


Leu Asp Pro Arg Gly Ile Tyr Arg Cys Asn Gly Thr Asp Ile Tyr Lys 
65                  70                  75                  80  


Asp Lys Glu Ser Thr Val Gln Val His Tyr Arg Met Cys Gln Ser Cys 
                85                  90                  95      


Val Glu Leu Asp Pro Ala Thr Val Ala Gly Ile Ile Val Thr Asp Val 
            100                 105                 110         


Ile Ala Thr Leu Leu Leu Ala Leu Gly Val Phe Cys Phe Ala Gly His 
        115                 120                 125             


Glu Thr Gly Arg Leu Ser Gly Ala Ala Asp Thr Gln Ala Leu Leu Arg 
    130                 135                 140                 


Asn Asp Gln Val Tyr Gln Pro Leu Arg Asp Arg Asp Asp Ala Gln Tyr 
145                 150                 155                 160 


Ser His Leu Gly Gly Asn Trp Ala Arg Asn Lys 
                165                 170     


<210>  87
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "11F9-F8" anti-CD3 antibody

<400>  87

Asp Val Val Leu Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asn Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Ala His Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  88
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "11F9-F8" anti-CD3 antibody

<400>  88

Gly Gln Gly Ala His Tyr Pro Phe Thr 
1               5                   


<210>  89
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "3G5-E10" anti-CD3 antibody

<400>  89

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Val Tyr 
            20                  25                  30          


Trp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Lys Lys Asp Ser Asn Ser Ile Asn Tyr Thr Pro Ser Leu 
    50                  55                  60                  


Lys Glu Lys Phe Thr Ile Ser Arg Asp Asn Ala Gln Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Val Asn Lys Leu Gly Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Glu Arg Asp Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Val 
            100                 105                 110         


Met Val Thr Val Ser Ser 
        115             


<210>  90
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "3G5-E10" anti-CD3 antibody

<400>  90

Gly Phe Asn Phe Asn Val Tyr Trp 
1               5               


<210>  91
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "3G5-E10" anti-CD3 antibody

<400>  91

Ile Lys Lys Asp Ser Asn Ser Ile 
1               5               


<210>  92
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "3G5-E10" anti-CD3 antibody

<400>  92

Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly 
1               5                   10                  15      


Glu Arg Val Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr 
            20                  25                  30          


Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  93
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "3G5-E10" anti-CD3 antibody

<400>  93

Glu Asn Val Val Thr Tyr 
1               5       


<210>  94
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "3G5-E10" anti-CD3 antibody

<400>  94

Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr 
1               5                   


<210>  95
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "9D7-F3" anti-CD3 antibody

<400>  95

Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Arg Ile Arg Thr Lys Pro Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Thr Gly Arg Phe Ile Ile Ser Arg Asp Asp Ser Arg Ser Met 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asp Asn Leu Gln Thr Glu Asp Thr Ala Met Tyr 
                85                  90                  95      


Tyr Cys Thr Ala Leu Ile Ser Thr Ala Met Ala Ala Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  96
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "9D7-F3" anti-CD3 antibody

<400>  96

Gly Phe Thr Phe Ser Asn Ala Ala 
1               5               


<210>  97
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "9D7-F3" anti-CD3 antibody

<400>  97

Ile Arg Thr Lys Pro Asn Asn Tyr Ala Thr 
1               5                   10  


<210>  98
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "9D7-F3" anti-CD3 antibody

<400>  98

Thr Ala Leu Ile Ser Thr Ala Met Ala Ala 
1               5                   10  


<210>  99
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "9D7-F3" anti-CD3 antibody

<400>  99

Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asn Ile Asn Lys Tyr 
            20                  25                  30          


Leu Asn Trp Tyr His Gln Met Leu Gly Glu Ala Pro Lys Leu Val Ile 
        35                  40                  45              


Ser Asn Thr Asn Asn Leu Gln Ala Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Phe Cys Leu Gln His Arg Ser Gly Tyr Thr 
                85                  90                  95      


Phe Gly Leu Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  100
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "9D7-F3" and "6C9-C9" anti-CD3 antibody

<400>  100

Gln Asn Ile Asn Lys Tyr 
1               5       


<210>  101
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "9D7-F3" anti-CD3 antibody

<400>  101

Leu Gln His Arg Ser Gly Tyr Thr 
1               5               


<210>  102
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "8C2-F7" anti-CD3 antibody

<400>  102

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Phe 
            20                  25                  30          


Ala Met Asn Trp Val Lys Gln Ala Pro Gly Asn Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Gln Thr Gly Lys Pro Thr Tyr Ala Asp Gly Phe 
    50                  55                  60                  


Lys Gln Arg Phe Val Phe Ser Leu Glu Thr Ser Ala Ser Thr Ile Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Asn Ile Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Thr Arg Gly Ala Leu Ala Ser Val Gly Gln Gly Val Leu Val Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  103
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "8C2-F7" anti-CD3 antibody

<400>  103

Gly Tyr Thr Phe Thr Asp Phe Ala 
1               5               


<210>  104
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "8C2-F7" anti-CD3 antibody

<400>  104

Ile Asn Thr Gln Thr Gly Lys Pro 
1               5               


<210>  105
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "8C2-F7" anti-CD3 antibody

<400>  105

Thr Arg Gly Ala Leu Ala Ser 
1               5           


<210>  106
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "8C2-F7" anti-CD3 antibody

<400>  106

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Ser His Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile 
65                  70                  75                  80  


Asn Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Ala Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  107
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "20E5-F10" anti-CD3 antibody

<400>  107

Glu Val Gln Leu Val Glu Thr Gly Glu Asn Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Arg Leu Thr Cys Ala Thr Ser Gly Phe Ser Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Ile Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Asn Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Ile Tyr Leu His Met Asp Asn Leu Lys Glu Glu Asp Ser Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Tyr Val His Tyr Gly Val Arg Phe Phe Tyr Thr Met Asp 
            100                 105                 110         


Val Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120                 


<210>  108
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "20E5-F10" anti-CD3 antibody

<400>  108

Arg Tyr Val His Tyr Gly Val Arg Phe Phe Tyr Thr Met Asp Val 
1               5                   10                  15  


<210>  109
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "20E5-F10" anti-CD3 antibody

<400>  109

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Val Ser Ile Ser Cys Arg Pro Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro His Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  110
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "20B5-F10" anti-CD3 antibody

<400>  110

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Ile Ser Ser 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Asn Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Gly Phe Leu Gly Met Asp Ala Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  111
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "20B5-F10" anti-CD3 antibody

<400>  111

Arg Gly Val Tyr Tyr Gly Phe Leu Gly Met Asp Ala 
1               5                   10          


<210>  112
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "20B5-F10" anti-CD3 antibody

<400>  112

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Arg Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Val Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  113
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "20B5-F10" anti-CD3 antibody

<400>  113

Gln Arg Leu Val His Asn Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  114
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "20B5-F10" anti-CD3 antibody

<400>  114

Gly Gln Gly Thr Glu Tyr Pro Phe Thr 
1               5                   


<210>  115
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "6C9-C9" anti-CD3 antibody

<400>  115

Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Arg Pro Lys Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Ala 
            20                  25                  30          


Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Arg Ile Arg Thr Gln Pro Asn Asn Tyr Ala Lys Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Met 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asp Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr 
                85                  90                  95      


Tyr Cys Thr Gly Leu Val Val Thr Ala Met Asp Ala Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  116
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "6C9-C9" anti-CD3 antibody

<400>  116

Gly Phe Thr Phe Arg Asn Ala Ala 
1               5               


<210>  117
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "6C9-C9" anti-CD3 antibody

<400>  117

Ile Arg Thr Gln Pro Asn Asn Tyr Ala Lys 
1               5                   10  


<210>  118
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "6C9-C9" anti-CD3 antibody

<400>  118

Thr Gly Leu Val Val Thr Ala Met Asp Ala 
1               5                   10  


<210>  119
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "6C9-C9" anti-CD3 antibody

<400>  119

Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asn Ile Asn Lys Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Leu Gly Glu Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Val Thr Asn Asn Leu Gln Thr Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Phe Cys Leu Gln His Arg Ser Met Tyr Thr 
                85                  90                  95      


Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  120
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "6C9-C9" anti-CD3 antibody

<400>  120

Leu Gln His Arg Ser Met Tyr Thr 
1               5               


<210>  121
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH the so-called "3E8-G1" anti-CD3 antibody

<400>  121

Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Tyr Met Asp Trp Val Arg Gln Ala Pro Lys Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Thr Ala Ser Gly Ser Arg Ile Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr 
65                  70                  75                  80  


Leu Leu Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Arg Thr Asp Ala Tyr Phe Asp Tyr Trp Gly Gln Gly Val 
            100                 105                 110         


Met Val Thr Val Ser Ser 
        115             


<210>  122
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "3E8-G1" anti-CD3 antibody

<400>  122

Gly Phe Thr Phe Ser Asn Tyr Tyr 
1               5               


<210>  123
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "3E8-G1" anti-CD3 antibody

<400>  123

Ile Thr Ala Ser Gly Ser Arg Ile 
1               5               


<210>  124
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "3E8-G1" anti-CD3 antibody

<400>  124

Ala Arg Glu Arg Thr Asp Ala Tyr Phe Asp Tyr 
1               5                   10      


<210>  125
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "3E8-G1" anti-CD3 antibody

<400>  125

Gln Phe Ile Leu Thr Gln Pro Asn Ser Val Ser Thr Ile Leu Gly Ser 
1               5                   10                  15      


Thr Val Lys Leu Ser Cys Lys Arg Ser Thr Gly Asn Ile Gly Thr Asn 
            20                  25                  30          


Tyr Val Ser Trp Tyr Gln His His Glu Gly Arg Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn 
65                  70                  75                  80  


Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ile Ser 
                85                  90                  95      


Gly Leu Asn Pro Val Phe Gly Gly Gly Ser Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  126
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "3E8-G1" anti-CD3 antibody

<400>  126

Thr Gly Asn Ile Gly Thr Asn Tyr 
1               5               


<210>  127
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "3E8-G1" anti-CD3 antibody

<400>  127

Gln Ser Tyr Ile Ser Gly Leu Asn Pro Val 
1               5                   10  


<210>  128
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "3H6-D2" anti-CD3 antibody.

<400>  128

Glu Val Gln Leu Val Glu Thr Gly Gly Arg Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Ala Leu Thr Tyr Tyr Gly Tyr Lys Arg Asp Ala Met Asp 
            100                 105                 110         


Gly Trp Gly His Gly Thr Ser Val Thr Val Ser Ser 
        115                 120                 


<210>  129
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "3H6-D2" anti-CD3 antibody

<400>  129

Arg Ala Leu Thr Tyr Tyr Gly Tyr Lys Arg Asp Ala Met Asp Gly 
1               5                   10                  15  


<210>  130
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "3H6-D2" anti-CD3 antibody.

<400>  130

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


<210>  131
<211>  114
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "8H2" anti-CD3 antibody

<400>  131

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Phe 
            20                  25                  30          


Ala Met Asn Trp Val Lys Gln Ala Pro Gly Asn Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Gln Thr Gly Lys Pro Thr Tyr Ala Asp Gly Phe 
    50                  55                  60                  


Lys Gln Arg Phe Val Phe Ser Leu Glu Thr Ser Ala Ser Thr Ile Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Asn Ile Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Thr Arg Gly Ala Leu Ala Ser Val Gly Gln Gly Val Met Val Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  132
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "8H2" anti-CD3 antibody

<400>  132

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ala Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val Gly Thr 
            20                  25                  30          


Ser Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Ile Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Thr Asp Asp Leu Gly Val Tyr Tyr Cys Leu Gln Gly 
                85                  90                  95      


Ser His Phe Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  133
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "8H2" anti-CD3 antibody

<400>  133

Gln Ser Leu Val Gly Thr Ser Gly Lys Thr Tyr 
1               5                   10      


<210>  134
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "8H2" anti-CD3 antibody

<400>  134

Leu Gln Gly Ser His Phe Pro Leu Thr 
1               5                   


<210>  135
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1a of humanized "20G6" anti-CD3 antibody

<400>  135

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  136
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1b of humanized "20G6" anti-CD3 antibody.

<400>  136

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  137
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1c of humanized "20G6" anti-CD3 antibody.

<400>  137

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Ala 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  138
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1d of humanized "20G6" anti-CD3 antibody

<400>  138

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  139
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1a of humanized "20G6" anti-CD3 antibody

<400>  139

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  140
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1b of humanized "20G6" anti-CD3 antibody

<400>  140

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  141
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1c of humanized "20G6" anti-CD3 antibody.

<400>  141

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Ala Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  142
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the VL1c variant of the humanized "20G6" anti-CD3 
       antibody.

<400>  142

Gln Ser Leu Val His Asn Asn Ala Asn Thr Tyr 
1               5                   10      


<210>  143
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1d of humanized "20G6" anti-CD3 antibody

<400>  143

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  144
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH2a of humanized "20G6" anti-CD3 antibody

<400>  144

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  145
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH2b of humanized "20G6" anti-CD3 antibody.

<400>  145

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  146
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH2c of humanized "20G6" anti-CD3 antibody

<400>  146

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ser Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Ala 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  147
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH2d of humanized "20G6" anti-CD3 antibody

<400>  147

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ser Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  148
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2a of humanized "20G6" anti-CD3 antibody

<400>  148

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  149
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2b of humanized "20G6" anti-CD3 antibody

<400>  149

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  150
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2c of humanized "20G6" anti-CD3 antibody

<400>  150

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  151
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2d of humanized "20G6" anti-CD3 antibody

<400>  151

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  152
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH3a of humanized "20G6" anti-CD3 antibody

<400>  152

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Gln 
    50                  55                  60                  


Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr 
65                  70                  75                  80  


Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  153
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH3b of humanized "20G6" anti-CD3 antibody

<400>  153

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Met 
        35                  40                  45              


Gly Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Gln 
    50                  55                  60                  


Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr 
65                  70                  75                  80  


Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  154
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL3a of humanized "20G6" anti-CD3 antibody

<400>  154

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Glu Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
65                  70                  75                  80  


Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  155
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL3b of humanized "20G6" anti-CD3 antibody

<400>  155

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Glu Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
65                  70                  75                  80  


Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  156
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL3c of humanized "20G6" anti-CD3 antibody

<400>  156

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
65                  70                  75                  80  


Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  157
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL3d of humanized "20G6" anti-CD3 antibody

<400>  157

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
65                  70                  75                  80  


Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  158
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1A of humanized "4B4" anti-CD3 antibody

<400>  158

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Val Gly 
1               5                   10                  15      


Gly Arg Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Lys Ser 
        35                  40                  45              


Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Ser 
    50                  55                  60                  


Ser Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Ser Val Gln Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  159
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1B of humanized "4B4" anti-CD3 antibody.

<400>  159

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Val Gly 
1               5                   10                  15      


Gly Arg Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Ala Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Lys Ser 
        35                  40                  45              


Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Ser 
    50                  55                  60                  


Ser Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Ser Val Gln Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  160
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2A of humanized "4B4" anti-CD3 antibody

<400>  160

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Gly Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Ser 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  161
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2B of humanized "4B4" anti-CD3 antibody

<400>  161

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Gly Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Ala Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Ser 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  162
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1Cmodif1 of humanized "4B4" anti-CD3 antibody

<400>  162

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  163
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1Cmodif2 of humanized "4B4" anti-CD3 antibody

<400>  163

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  164
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1Cmodif3 of humanized "4B4" anti-CD3 antibody

<400>  164

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Ala Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  165
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1Amodif1of humanized "4B4" anti-CD3 antibody

<400>  165

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  166
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1Amodif2of humanized "4B4" anti-CD3 antibody

<400>  166

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  167
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1Amodif3 of humanized "4B4" anti-CD3 antibody

<400>  167

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  168
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2C of humanized "4B4" anti-CD3 antibody

<400>  168

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  169
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2D of humanized "4B4" anti-CD3 antibody

<400>  169

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  170
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2F of humanized "4B4" anti-CD3 antibody

<400>  170

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Ala Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  171
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1A of humanized "4B4" anti-CD3 antibody

<400>  171

Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Lys Pro Gly Gln 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Thr Pro Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  172
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1B of humanized "4B4" anti-CD3 antibody

<400>  172

Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Lys Pro Gly Gln 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Val 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Thr Pro Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  173
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH2A of humanized "4B4" anti-CD3 antibody

<400>  173

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  174
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH2B of humanized "4B4" anti-CD3 antibody

<400>  174

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser 
        115                 120     


<210>  175
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH6Bmodif1 of humanized "4B4" anti-CD3 antibody

<400>  175

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  176
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH6Bmodif2 of humanized "4B4" anti-CD3 antibody

<400>  176

Gln Val Gln Leu Val Glu Ser Gly Gly Arg Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Thr Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  177
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH6Amodif1 of humanized "4B4" anti-CD3 antibody

<400>  177

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  178
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH6Amodif2 of humanized "4B4" anti-CD3 antibody

<400>  178

Gln Val Gln Leu Val Glu Ser Gly Gly Arg Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Thr Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  179
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH6Amodif3 of humanized "4B4" anti-CD3 antibody

<400>  179

Gln Val Gln Leu Val Glu Ser Gly Gly Arg Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Thr Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  180
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH6C of humanized "4B4" anti-CD3 antibody

<400>  180

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  181
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH6D of humanized "4B4" anti-CD3 antibody

<400>  181

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  182
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL "D7-VK3mut" of humanized "4B4" anti-CD3 antibody

<400>  182

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Gln Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  183
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D7-VH1mut of humanized "4B4" anti-CD3 antibody

<400>  183

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Gly Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  184
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the VL1B, VL2B, VL1Cmofif3 and VL2F variants of the 
       humanized "4B4" anti-CD3 antibody

<400>  184

Gln Ser Leu Val His Asp Asn Ala Asn Thr Tyr 
1               5                   10      


<210>  185
<211>  182
<212>  PRT
<213>  Homo sapiens

<400>  185

Met Glu Gln Gly Lys Gly Leu Ala Val Leu Ile Leu Ala Ile Ile Leu 
1               5                   10                  15      


Leu Gln Gly Thr Leu Ala Gln Ser Ile Lys Gly Asn His Leu Val Lys 
            20                  25                  30          


Val Tyr Asp Tyr Gln Glu Asp Gly Ser Val Leu Leu Thr Cys Asp Ala 
        35                  40                  45              


Glu Ala Lys Asn Ile Thr Trp Phe Lys Asp Gly Lys Met Ile Gly Phe 
    50                  55                  60                  


Leu Thr Glu Asp Lys Lys Lys Trp Asn Leu Gly Ser Asn Ala Lys Asp 
65                  70                  75                  80  


Pro Arg Gly Met Tyr Gln Cys Lys Gly Ser Gln Asn Lys Ser Lys Pro 
                85                  90                  95      


Leu Gln Val Tyr Tyr Arg Met Cys Gln Asn Cys Ile Glu Leu Asn Ala 
            100                 105                 110         


Ala Thr Ile Ser Gly Phe Leu Phe Ala Glu Ile Val Ser Ile Phe Val 
        115                 120                 125             


Leu Ala Val Gly Val Tyr Phe Ile Ala Gly Gln Asp Gly Val Arg Gln 
    130                 135                 140                 


Ser Arg Ala Ser Asp Lys Gln Thr Leu Leu Pro Asn Asp Gln Leu Tyr 
145                 150                 155                 160 


Gln Pro Leu Lys Asp Arg Glu Asp Asp Gln Tyr Ser His Leu Gln Gly 
                165                 170                 175     


Asn Gln Leu Arg Arg Asn 
            180         


<210>  186
<211>  249
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain sequence of "20G6-F3" Fab

<400>  186

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
        115                 120                 125             


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 
    130                 135                 140                 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
145                 150                 155                 160 


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
                165                 170                 175     


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
            180                 185                 190         


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 
        195                 200                 205             


Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 
    210                 215                 220                 


Asp Lys Thr His Thr Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn 
225                 230                 235                 240 


Gly Ala Ala His His His His His His 
                245                 


<210>  187
<211>  219
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain sequence of "20G6-F3" Fab

<400>  187

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Asp Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
        115                 120                 125             


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
    130                 135                 140                 


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
145                 150                 155                 160 


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
                165                 170                 175     


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
            180                 185                 190         


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
        195                 200                 205             


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
    210                 215                 


<210>  188
<211>  250
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain sequence of "4E7-C9" Fab

<400>  188

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Pro Lys Arg Ser 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Arg Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Tyr Val His Tyr Gly Ile Gly Tyr Ala Met Asp Ala Trp 
            100                 105                 110         


Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 
        115                 120                 125             


Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 
    130                 135                 140                 


Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 
145                 150                 155                 160 


Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 
                165                 170                 175     


Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 
            180                 185                 190         


Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 
        195                 200                 205             


His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 
    210                 215                 220                 


Cys Asp Lys Thr His Thr Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 
225                 230                 235                 240 


Asn Gly Ala Ala His His His His His His 
                245                 250 


<210>  189
<211>  219
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain sequence of "4E7-C9" Fab

<400>  189

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
        115                 120                 125             


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
    130                 135                 140                 


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
145                 150                 155                 160 


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
                165                 170                 175     


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
            180                 185                 190         


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
        195                 200                 205             


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
    210                 215                 


<210>  190
<211>  249
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain sequence of "4B4-D7" Fab

<400>  190

Glu Val Gln Leu Val Glu Thr Gly Gly Arg Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 
        115                 120                 125             


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 
    130                 135                 140                 


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 
145                 150                 155                 160 


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 
                165                 170                 175     


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 
            180                 185                 190         


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 
        195                 200                 205             


Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 
    210                 215                 220                 


Asp Lys Thr His Thr Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn 
225                 230                 235                 240 


Gly Ala Ala His His His His His His 
                245                 


<210>  191
<211>  218
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain sequence of "4B4-D7 "  Fab

<400>  191

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Thr Ser 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
        115                 120                 125             


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
    130                 135                 140                 


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
145                 150                 155                 160 


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
                165                 170                 175     


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
            180                 185                 190         


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
        195                 200                 205             


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu 
    210                 215             


<210>  192
<211>  250
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain sequence of "18F5-H10" Fab

<400>  192

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Thr Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Arg Ser Pro Glu Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Tyr Val His Tyr Arg Phe Ala Tyr Ala Leu Asp Ala Trp 
            100                 105                 110         


Gly Arg Gly Thr Ser Val Ser Val Ser Ser Ala Ser Thr Lys Gly Pro 
        115                 120                 125             


Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 
    130                 135                 140                 


Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 
145                 150                 155                 160 


Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 
                165                 170                 175     


Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 
            180                 185                 190         


Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 
        195                 200                 205             


His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 
    210                 215                 220                 


Cys Asp Lys Thr His Thr Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 
225                 230                 235                 240 


Asn Gly Ala Ala His His His His His His 
                245                 250 


<210>  193
<211>  219
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  light chain sequence of "18F5-H10"  Fab

<400>  193

Asp Val Leu Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Thr 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr His Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
        115                 120                 125             


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
    130                 135                 140                 


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
145                 150                 155                 160 


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
                165                 170                 175     


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
            180                 185                 190         


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
        195                 200                 205             


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
    210                 215                 


<210>  194
<211>  378
<212>  PRT
<213>  Homo sapiens

<400>  194

Met Val Leu Leu Trp Leu Thr Leu Leu Leu Ile Ala Leu Pro Cys Leu 
1               5                   10                  15      


Leu Gln Thr Lys Glu Asp Pro Asn Pro Pro Ile Thr Asn Leu Arg Met 
            20                  25                  30          


Lys Ala Lys Ala Gln Gln Leu Thr Trp Asp Leu Asn Arg Asn Val Thr 
        35                  40                  45              


Asp Ile Glu Cys Val Lys Asp Ala Asp Tyr Ser Met Pro Ala Val Asn 
    50                  55                  60                  


Asn Ser Tyr Cys Gln Phe Gly Ala Ile Ser Leu Cys Glu Val Thr Asn 
65                  70                  75                  80  


Tyr Thr Val Arg Val Ala Asn Pro Pro Phe Ser Thr Trp Ile Leu Phe 
                85                  90                  95      


Pro Glu Asn Ser Gly Lys Pro Trp Ala Gly Ala Glu Asn Leu Thr Cys 
            100                 105                 110         


Trp Ile His Asp Val Asp Phe Leu Ser Cys Ser Trp Ala Val Gly Pro 
        115                 120                 125             


Gly Ala Pro Ala Asp Val Gln Tyr Asp Leu Tyr Leu Asn Val Ala Asn 
    130                 135                 140                 


Arg Arg Gln Gln Tyr Glu Cys Leu His Tyr Lys Thr Asp Ala Gln Gly 
145                 150                 155                 160 


Thr Arg Ile Gly Cys Arg Phe Asp Asp Ile Ser Arg Leu Ser Ser Gly 
                165                 170                 175     


Ser Gln Ser Ser His Ile Leu Val Arg Gly Arg Ser Ala Ala Phe Gly 
            180                 185                 190         


Ile Pro Cys Thr Asp Lys Phe Val Val Phe Ser Gln Ile Glu Ile Leu 
        195                 200                 205             


Thr Pro Pro Asn Met Thr Ala Lys Cys Asn Lys Thr His Ser Phe Met 
    210                 215                 220                 


His Trp Lys Met Arg Ser His Phe Asn Arg Lys Phe Arg Tyr Glu Leu 
225                 230                 235                 240 


Gln Ile Gln Lys Arg Met Gln Pro Val Ile Thr Glu Gln Val Arg Asp 
                245                 250                 255     


Arg Thr Ser Phe Gln Leu Leu Asn Pro Gly Thr Tyr Thr Val Gln Ile 
            260                 265                 270         


Arg Ala Arg Glu Arg Val Tyr Glu Phe Leu Ser Ala Trp Ser Thr Pro 
        275                 280                 285             


Gln Arg Phe Glu Cys Asp Gln Glu Glu Gly Ala Asn Thr Arg Ala Trp 
    290                 295                 300                 


Arg Thr Ser Leu Leu Ile Ala Leu Gly Thr Leu Leu Ala Leu Val Cys 
305                 310                 315                 320 


Val Phe Val Ile Cys Arg Arg Tyr Leu Val Met Gln Arg Leu Phe Pro 
                325                 330                 335     


Arg Ile Pro His Met Lys Asp Pro Ile Gly Asp Ser Phe Gln Asn Asp 
            340                 345                 350         


Lys Leu Val Val Trp Glu Ala Gly Lys Ala Gly Leu Glu Glu Cys Leu 
        355                 360                 365             


Val Thr Glu Val Gln Val Val Gln Lys Thr 
    370                 375             


<210>  195
<211>  378
<212>  PRT
<213>  Macaca fascicularis

<400>  195

Met Thr Leu Leu Trp Leu Thr Leu Leu Leu Val Ala Thr Pro Cys Leu 
1               5                   10                  15      


Leu Arg Thr Lys Glu Asp Pro Asn Ala Pro Ile Arg Asn Leu Arg Met 
            20                  25                  30          


Lys Glu Lys Ala Gln Gln Leu Met Trp Asp Leu Asn Arg Asn Val Thr 
        35                  40                  45              


Asp Val Glu Cys Ile Lys Gly Thr Asp Tyr Ser Met Pro Ala Met Asn 
    50                  55                  60                  


Asn Ser Tyr Cys Gln Phe Gly Ala Ile Ser Leu Cys Glu Val Thr Asn 
65                  70                  75                  80  


Tyr Thr Val Arg Val Ala Ser Pro Pro Phe Ser Thr Trp Ile Leu Phe 
                85                  90                  95      


Pro Glu Asn Ser Gly Thr Pro Arg Ala Gly Ala Glu Asn Leu Thr Cys 
            100                 105                 110         


Trp Val His Asp Val Asp Phe Leu Ser Cys Ser Trp Val Val Gly Pro 
        115                 120                 125             


Ala Ala Pro Ala Asp Val Gln Tyr Asp Leu Tyr Leu Asn Asn Pro Asn 
    130                 135                 140                 


Ser His Glu Gln Tyr Arg Cys Leu His Tyr Lys Thr Asp Ala Arg Gly 
145                 150                 155                 160 


Thr Gln Ile Gly Cys Arg Phe Asp Asp Ile Ala Pro Leu Ser Arg Gly 
                165                 170                 175     


Ser Gln Ser Ser His Ile Leu Val Arg Gly Arg Ser Ala Ala Val Ser 
            180                 185                 190         


Ile Pro Cys Thr Asp Lys Phe Val Phe Phe Ser Gln Ile Glu Arg Leu 
        195                 200                 205             


Thr Pro Pro Asn Met Thr Gly Glu Cys Asn Glu Thr His Ser Phe Met 
    210                 215                 220                 


His Trp Lys Met Lys Ser His Phe Asn Arg Lys Phe Arg Tyr Glu Leu 
225                 230                 235                 240 


Arg Ile Gln Lys Arg Met Gln Pro Val Arg Thr Glu Gln Val Arg Asp 
                245                 250                 255     


Thr Thr Ser Phe Gln Leu Pro Asn Pro Gly Thr Tyr Thr Val Gln Ile 
            260                 265                 270         


Arg Ala Arg Glu Thr Val Tyr Glu Phe Leu Ser Ala Trp Ser Thr Pro 
        275                 280                 285             


Gln Arg Phe Glu Cys Asp Gln Glu Glu Gly Ala Ser Ser Arg Ala Trp 
    290                 295                 300                 


Arg Thr Ser Leu Leu Ile Ala Leu Gly Thr Leu Leu Ala Leu Leu Cys 
305                 310                 315                 320 


Val Phe Leu Ile Cys Arg Arg Tyr Leu Val Met Gln Arg Leu Phe Pro 
                325                 330                 335     


Arg Ile Pro His Met Lys Asp Pro Ile Gly Asp Thr Phe Gln Gln Asp 
            340                 345                 350         


Lys Leu Val Val Trp Glu Ala Gly Lys Ala Gly Leu Glu Glu Cys Leu 
        355                 360                 365             


Val Ser Glu Val Gln Val Val Glu Lys Thr 
    370                 375             


<210>  196
<211>  523
<212>  PRT
<213>  Homo sapiens


<220>
<221>  DOMAIN
<222>  (1)..(284)
<223>  extracellular domain of human CD123

<220>
<221>  MISC_FEATURE
<222>  (285)..(519)
<223>  Strep-II tagged Fc-Fusion

<400>  196

Thr Lys Glu Asp Pro Asn Pro Pro Ile Thr Asn Leu Arg Met Lys Ala 
1               5                   10                  15      


Lys Ala Gln Gln Leu Thr Trp Asp Leu Asn Arg Asn Val Thr Asp Ile 
            20                  25                  30          


Glu Cys Val Lys Asp Ala Asp Tyr Ser Met Pro Ala Val Asn Asn Ser 
        35                  40                  45              


Tyr Cys Gln Phe Gly Ala Ile Ser Leu Cys Glu Val Thr Asn Tyr Thr 
    50                  55                  60                  


Val Arg Val Ala Asn Pro Pro Phe Ser Thr Trp Ile Leu Phe Pro Glu 
65                  70                  75                  80  


Asn Ser Gly Lys Pro Trp Ala Gly Ala Glu Asn Leu Thr Cys Trp Ile 
                85                  90                  95      


His Asp Val Asp Phe Leu Ser Cys Ser Trp Ala Val Gly Pro Gly Ala 
            100                 105                 110         


Pro Ala Asp Val Gln Tyr Asp Leu Tyr Leu Asn Val Ala Asn Arg Arg 
        115                 120                 125             


Gln Gln Tyr Glu Cys Leu His Tyr Lys Thr Asp Ala Gln Gly Thr Arg 
    130                 135                 140                 


Ile Gly Cys Arg Phe Asp Asp Ile Ser Arg Leu Ser Ser Gly Ser Gln 
145                 150                 155                 160 


Ser Ser His Ile Leu Val Arg Gly Arg Ser Ala Ala Phe Gly Ile Pro 
                165                 170                 175     


Cys Thr Asp Lys Phe Val Val Phe Ser Gln Ile Glu Ile Leu Thr Pro 
            180                 185                 190         


Pro Asn Met Thr Ala Lys Cys Asn Lys Thr His Ser Phe Met His Trp 
        195                 200                 205             


Lys Met Arg Ser His Phe Asn Arg Lys Phe Arg Tyr Glu Leu Gln Ile 
    210                 215                 220                 


Gln Lys Arg Met Gln Pro Val Ile Thr Glu Gln Val Arg Asp Arg Thr 
225                 230                 235                 240 


Ser Phe Gln Leu Leu Asn Pro Gly Thr Tyr Thr Val Gln Ile Arg Ala 
                245                 250                 255     


Arg Glu Arg Val Tyr Glu Phe Leu Ser Ala Trp Ser Thr Pro Gln Arg 
            260                 265                 270         


Phe Glu Cys Asp Gln Glu Glu Gly Ala Asn Thr Arg Ala Trp Arg Asp 
        275                 280                 285             


Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 
    290                 295                 300                 


Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 
305                 310                 315                 320 


Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 
                325                 330                 335     


Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 
            340                 345                 350         


Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 
        355                 360                 365             


Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 
    370                 375                 380                 


Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 
385                 390                 395                 400 


Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 
                405                 410                 415     


Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu 
            420                 425                 430         


Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 
        435                 440                 445             


Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 
    450                 455                 460                 


Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 
465                 470                 475                 480 


Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 
                485                 490                 495     


Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 
            500                 505                 510         


Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys 
        515                 520             


<210>  197
<211>  519
<212>  PRT
<213>  Macaca fascicularis


<220>
<221>  DOMAIN
<222>  (1)..(284)
<223>  extracellular domain of Macaca fascicularis CD123

<220>
<221>  MISC_FEATURE
<222>  (285)..(516)
<223>  Strep-II tagged Fc-fusion

<400>  197

Thr Lys Glu Asp Pro Asn Ala Pro Ile Arg Asn Leu Arg Met Lys Glu 
1               5                   10                  15      


Lys Ala Gln Gln Leu Met Trp Asp Leu Asn Arg Asn Val Thr Asp Val 
            20                  25                  30          


Glu Cys Ile Lys Gly Thr Asp Tyr Ser Met Pro Ala Met Asn Asn Ser 
        35                  40                  45              


Tyr Cys Gln Phe Gly Ala Ile Ser Leu Cys Glu Val Thr Asn Tyr Thr 
    50                  55                  60                  


Val Arg Val Ala Ser Pro Pro Phe Ser Thr Trp Ile Leu Phe Pro Glu 
65                  70                  75                  80  


Asn Thr Gly Thr Pro Arg Ala Gly Ala Glu Asn Leu Thr Cys Trp Val 
                85                  90                  95      


His Asp Val Asp Phe Leu Ser Cys Ser Trp Val Val Gly Pro Ala Ala 
            100                 105                 110         


Pro Ala Asp Val Gln Tyr Asp Leu Tyr Leu Asn Asn Pro Asn Ser His 
        115                 120                 125             


Glu Gln Tyr Arg Cys Leu His Tyr Lys Thr Asp Ala Arg Gly Thr Gln 
    130                 135                 140                 


Ile Gly Cys Arg Phe Asp Asp Ile Ala Arg Leu Ser Arg Gly Ser Gln 
145                 150                 155                 160 


Ser Ser His Ile Leu Val Arg Gly Arg Ser Ala Ala Val Ser Ile Pro 
                165                 170                 175     


Cys Thr Asp Lys Phe Val Phe Phe Ser Gln Ile Glu Arg Leu Thr Pro 
            180                 185                 190         


Pro Asn Met Thr Gly Glu Cys Asn Glu Thr His Ser Phe Met His Trp 
        195                 200                 205             


Lys Met Lys Ser His Phe Asn Arg Lys Phe Arg Tyr Glu Leu Arg Ile 
    210                 215                 220                 


Gln Lys Arg Met Gln Pro Val Arg Thr Glu Gln Val Arg Asp Thr Thr 
225                 230                 235                 240 


Ser Phe Gln Leu Pro Asn Pro Gly Thr Tyr Thr Val Gln Ile Arg Ala 
                245                 250                 255     


Arg Glu Thr Val Tyr Glu Phe Leu Ser Ala Trp Ser Thr Pro Gln Arg 
            260                 265                 270         


Phe Glu Cys Asp Gln Glu Glu Gly Ala Ser Ser Arg Ala Trp Arg Gly 
        275                 280                 285             


Ser Gly Gly Ser Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
    290                 295                 300                 


Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
305                 310                 315                 320 


Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
                325                 330                 335     


Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 
            340                 345                 350         


Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
        355                 360                 365             


Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
    370                 375                 380                 


Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 
385                 390                 395                 400 


Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
                405                 410                 415     


Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 
            420                 425                 430         


Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 
        435                 440                 445             


Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
    450                 455                 460                 


Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
465                 470                 475                 480 


Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 
                485                 490                 495     


Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
            500                 505                 510         


Ser Leu Ser Leu Ser Pro Gly 
        515                 


<210>  198
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "1E1-G5" anti-CD123 antibody

<400>  198

Gln Val Gln Leu Gln Glu Ser Gly Pro Thr Leu Val Lys Pro Gly Asp 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Phe Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ile Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Ser Gly Gly Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Phe Ser Arg Leu Thr Ser Glu Asp Ser Ala Ile Cys Tyr Cys 
                85                  90                  95      


Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  199
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "1E1-G5" and "8B11-B7" anti-CD123 
       antibodies

<400>  199

Gly Tyr Thr Phe Thr Asp His Ile 
1               5               


<210>  200
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "1E1-G5" and "6D6-B8" anti-CD123 
       antibodies

<400>  200

Ile Asn Pro Tyr Ser Gly Gly Thr 
1               5               


<210>  201
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "1E1-G5", "6D6-B8", "8B11-B7" and 
       "9F6-G3" anti-CD123 antibodies

<400>  201

Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala 
1               5                   10          


<210>  202
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "1E1-G5" anti-CD123 antibody

<400>  202

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Gln Thr Val Thr Ile Glu Cys Arg Pro Ser Glu Asp Ile Tyr Ser Asn 
            20                  25                  30          


Leu Ala Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Asn Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Val Ala Ser Tyr Phe Cys Gln Gln Tyr Asn Lys Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  203
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "1E1-G5" anti-CD123 antibody

<400>  203

Glu Asp Ile Tyr Ser Asn 
1               5       


<210>  204
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "1E1-G5" anti-CD123 antibody

<400>  204

Gln Gln Tyr Asn Lys Tyr Pro Tyr Thr 
1               5                   


<210>  205
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "2B8-F3" anti-CD123 antibody

<400>  205

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 
            20                  25                  30          


Asn Met Ala Trp Val Arg Gln Ala Pro Lys Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Leu Tyr Asp Gly Gly Arg Thr Tyr Tyr Arg Gly Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Leu Tyr 
65                  70                  75                  80  


Leu Arg Met Asp Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Thr His Ser Arg Gly Thr Asp Tyr Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Val Met Val Thr Val Ser Ser 
        115                 


<210>  206
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "2B8-F3" anti-CD123 antibody

<400>  206

Gly Phe Thr Phe Ser Asp Tyr Asn 
1               5               


<210>  207
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "2B8-F3" anti-CD123 antibody

<400>  207

Ile Leu Tyr Asp Gly Gly Arg Thr 
1               5               


<210>  208
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "2B8-F3" anti-CD123 antibody

<400>  208

Ala Thr His Ser Arg Gly Thr Asp Tyr Phe Asp Tyr 
1               5                   10          


<210>  209
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "2B8-F3" anti-CD123 antibody

<400>  209

Glu Ile Val Leu Thr Gln Ser Pro Thr Ser Met Thr Ala Ser Pro Gly 
1               5                   10                  15      


Glu Gln Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Ile Asn Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Ala Ser Pro Arg Pro Trp Ile Tyr 
        35                  40                  45              


Glu Thr Ser Lys Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ala Ser Gly Thr Ser Tyr Ser Leu Thr Ile Asn Asn Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Tyr Pro Ser Trp Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  210
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "2B8-F3" anti-CD123 antibody

<400>  210

Ser Ser Ile Asn Tyr 
1               5   


<210>  211
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "2B8-F3" anti-CD123 antibody

<400>  211

Gln Gln Trp Asn Tyr Pro Ser Trp Thr 
1               5                   


<210>  212
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "2F8-D6" anti-CD123 antibody

<400>  212

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Ala Thr Ile Ser Ser Ala Gly Ser Thr Tyr Tyr Asp Leu Val Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ser Ile Thr Arg Asp Thr Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Val His Ser Leu Gln Thr Glu Asp Thr Ala Ile Tyr Leu Cys Ala 
                85                  90                  95      


Arg Asp Ala Pro Val Phe Asn Tyr Gly Ser Tyr Asn Ala Met Asp Ser 
            100                 105                 110         


Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120             


<210>  213
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "2F8-D6" anti-CD123 antibody

<400>  213

Gly Phe Ser Leu Thr Ser Tyr Gly 
1               5               


<210>  214
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "2F8-D6" anti-CD123 antibody

<400>  214

Ile Ser Ser Ala Gly Ser Thr 
1               5           


<210>  215
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "2F8-D6" anti-CD123 antibody

<400>  215

Ala Arg Asp Ala Pro Val Phe Asn Tyr Gly Ser Tyr Asn Ala Met Asp 
1               5                   10                  15      


Ser 
    


<210>  216
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "2F8-D6" anti-CD123 antibody

<400>  216

Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Thr Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asn Ile Asn Lys Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Leu Gly Glu Ala Pro Lys Arg Leu Ile 
        35                  40                  45              


Tyr Asn Thr Asn Ser Leu Gln Thr Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Phe Cys Leu Gln His Lys Ser Gly Leu Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  217
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "2F8-D6" anti-CD123 antibody

<400>  217

Gln Asn Ile Asn Lys Tyr 
1               5       


<210>  218
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "2F8-D6" anti-CD123 antibody

<400>  218

Leu Gln His Lys Ser Gly Leu Thr 
1               5               


<210>  219
<211>  125
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "3B10-E6" anti-CD123 antibody

<400>  219

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Arg Arg Pro Gly Ser 
1               5                   10                  15      


Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Tyr Arg Ile Lys Asp Phe 
            20                  25                  30          


Leu Ile His Trp Ile Lys Asn Arg Pro Glu His Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Asp Pro Glu Asp Gly Glu Thr Lys Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Thr Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Trp Gly Asp Val Tyr Tyr Gly Leu Met Arg Gly His Val Met 
            100                 105                 110         


Asp Ala Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120                 125 


<210>  220
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "3B10-E6" anti-CD123 antibody

<400>  220

Gly Tyr Arg Ile Lys Asp Phe Leu 
1               5               


<210>  221
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "3B10-E6" anti-CD123 antibody

<400>  221

Ile Asp Pro Glu Asp Gly Glu Thr 
1               5               


<210>  222
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "3B10-E6" anti-CD123 antibody

<400>  222

Ala Arg Trp Gly Asp Val Tyr Tyr Gly Leu Met Arg Gly His Val Met 
1               5                   10                  15      


Asp Ala 
        


<210>  223
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "3B10-E6" anti-CD123 antibody

<400>  223

Asp Val Leu Met Thr Gln Thr Pro Val Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 
            20                  25                  30          


Asp Gly Asp Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Glu Asp Leu Gly Leu Tyr Tyr Cys Leu Gln Thr 
                85                  90                  95      


Thr His Phe Pro Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Met 
            100                 105                 110         


Lys 
    


<210>  224
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "3B10-E6" anti-CD123 antibody

<400>  224

Gln Ser Leu Val His Ser Asp Gly Asp Thr Tyr 
1               5                   10      


<210>  225
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "3B10-E6" anti-CD123 antibody

<400>  225

Leu Gln Thr Thr His Phe Pro Pro Trp Thr 
1               5                   10  


<210>  226
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "3E3-D3" anti-CD123 antibody

<400>  226

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Gly Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ile Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Val Gln Thr Glu Asp Thr Ala Met Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  227
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "3E3-D3" anti-CD123 antibody

<400>  227

Gly Phe Ser Leu Thr Thr Tyr Asp 
1               5               


<210>  228
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "3E3-D3" anti-CD123 antibody

<400>  228

Ile Gln Asn Gly Gly Ile Thr 
1               5           


<210>  229
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "3E3-D3" anti-CD123 antibody

<400>  229

Ala Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His 
1               5                   10          


<210>  230
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "3E3-D3" anti-CD123 antibody

<400>  230

Gln Phe Val Leu Thr Gln Pro Asn Ser Val Ser Thr Asn Leu Gly Ser 
1               5                   10                  15      


Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln His Glu Gly Arg Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn 
65                  70                  75                  80  


Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  231
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "3E3-D3" anti-CD123 antibody

<400>  231

Thr Gly Asn Ile Gly Ser Asn Tyr 
1               5               


<210>  232
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "3E3-D3" anti-CD123 antibody

<400>  232

Gln Ser Tyr Ser Ser Gly Ile Asn Ile Ile 
1               5                   10  


<210>  233
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "5A5-B4" anti-CD123 antibody

<400>  233

Gln Ile Gln Ile Val Gln Ser Gly Ser Asp Val Thr Ser Thr Cys Asn 
1               5                   10                  15      


Gly Cys Gly Thr Cys Tyr Phe Ser Gly Phe Ser Leu Ser Thr Thr Gly 
            20                  25                  30          


Ile Cys Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Gln Glu Trp 
        35                  40                  45              


Leu Ala Asp Phe Cys Trp Asp Asp Gly Lys Gly Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Asn Arg Leu Ser Ile Ser Lys Asp Thr Ser Asn Asn Gln Val Phe 
65                  70                  75                  80  


Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Arg Val Tyr Tyr Gly Ile Tyr Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Val Met Val Thr Val Ser Ser 
        115                 120 


<210>  234
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "5A5-B4" anti-CD123 antibody

<400>  234

Gly Phe Ser Leu Ser Thr Thr Gly Ile Cys 
1               5                   10  


<210>  235
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "5A5-B4" anti-CD123 antibody

<400>  235

Phe Cys Trp Asp Asp Gly Lys 
1               5           


<210>  236
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "5A5-B4" anti-CD123 antibody

<400>  236

Ala Arg Arg Arg Val Tyr Tyr Gly Ile Tyr Phe Asp Tyr 
1               5                   10              


<210>  237
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "5A5-B4" anti-CD123 antibody

<400>  237

Asp Ile Val Met Thr Gln Ser Pro Ala Leu Ala Val Ser Pro Gly Glu 
1               5                   10                  15      


Arg Val Ser Ile Ser Cys Arg Ala Ser Asn Ser Val Ser Thr Arg Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Gln Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Ala Asp 
65                  70                  75                  80  


Asp Ile Ala Thr Tyr Phe Cys Gln Gln Ser Trp Asn Asp Pro Leu Thr 
                85                  90                  95      


Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  238
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "5A5-B4" anti-CD123 antibody

<400>  238

Asn Ser Val Ser Thr Arg 
1               5       


<210>  239
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "5A5-B4" anti-CD123 antibody

<400>  239

Gln Gln Ser Trp Asn Asp Pro Leu Thr 
1               5                   


<210>  240
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "6B10-E4" anti-CD123 antibody

<400>  240

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Tyr 
            20                  25                  30          


Asn Met Ala Trp Val Arg Gln Ala Pro Lys Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Thr Tyr Asp Asp His Ser Thr Tyr Tyr Arg Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Ser Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asp Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Val Asn Tyr Ala Phe Ala Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  241
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "6B10-E4" anti-CD123 antibody

<400>  241

Gly Phe Thr Phe Ser His Tyr Asn 
1               5               


<210>  242
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "6B10-E4" anti-CD123 antibody

<400>  242

Ile Thr Tyr Asp Asp His Ser Thr 
1               5               


<210>  243
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "6B10-E4" anti-CD123 antibody

<400>  243

Ala Arg Leu Val Asn Tyr Ala Phe Ala Tyr 
1               5                   10  


<210>  244
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "6B10-E4" anti-CD123 antibody

<400>  244

Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Ile Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Met Asn Cys Lys Ala Ser Gln Thr Val Gly Asn Asn 
            20                  25                  30          


Ile Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Asp Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asn Arg Phe Thr Gly 
    50                  55                  60                  


Gly Gly Tyr Gly Thr Asp Phe Ile Leu Thr Ile Asn Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Ala Ala Phe Tyr Tyr Cys Gln Arg Met Tyr Asn Ser Pro Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  245
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "6B10-E4" anti-CD123 antibody

<400>  245

Gln Thr Val Gly Asn Asn 
1               5       


<210>  246
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "6B10-E4" anti-CD123 antibody

<400>  246

Gln Arg Met Tyr Asn Ser Pro Thr 
1               5               


<210>  247
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "6C10-C4" anti-CD123 antibody

<400>  247

Glu Val Lys Leu Gln Glu Ser Gly Pro Ser Leu Val Gln Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Ser Val His Trp Val Arg Gln His Ser Gly Lys Ser Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Met Trp Asn Asp Gly Asp Thr Ser Tyr Asn Ser Ala Phe Thr 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Lys Gly Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Glu Asp Thr Gly Thr Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly His Arg Thr Pro Phe Asp Tyr Trp Gly Gln Gly Val Met Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  248
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "6C10-C4" anti-CD123 antibody

<400>  248

Gly Phe Ser Leu Thr Ser Tyr Ser 
1               5               


<210>  249
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "6C10-C4" anti-CD123 antibody

<400>  249

Met Trp Asn Asp Gly Asp Thr 
1               5           


<210>  250
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "6C10-C4" anti-CD123 antibody

<400>  250

Ala Arg Gly His Arg Thr Pro Phe Asp Tyr 
1               5                   10  


<210>  251
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "6C10-C4" and "9B8-G6" anti-CD123 antibodies

<400>  251

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Phe Leu Ser Ser 
            20                  25                  30          


Gly Asp Glu Arg Asn Tyr Val Ala Trp Tyr Gln His Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Ile Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Asp Thr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  252
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "6C10-C4" and "9B8-G6" anti-CD123 
       antibodies

<400>  252

Gln Ser Phe Leu Ser Ser Gly Asp Glu Arg Asn Tyr 
1               5                   10          


<210>  253
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "6C10-C4", "9B8-G6" and "9D7-G3" 
       anti-CD123 antibodies

<400>  253

Gln Gln Tyr Tyr Asp Thr Pro Leu Thr 
1               5                   


<210>  254
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "6D6-B8" anti-CD123 antibody

<400>  254

Gln Val Gln Leu Gln Glu Ser Gly Pro Thr Leu Val Lys Pro Gly Asp 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Ala Tyr Thr Phe Thr Asp Asn 
            20                  25                  30          


Ile Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Asp Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Ser Gly Gly Thr Asn Tyr Asn Gly Trp Phe 
    50                  55                  60                  


Arg Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Phe Ser Arg Leu Thr Ser Asp Asp Ser Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  255
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "6D6-B8" anti-CD123 antibody

<400>  255

Ala Tyr Thr Phe Thr Asp Asn Ile 
1               5               


<210>  256
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "6D6-B8" anti-CD123 antibody

<400>  256

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Asp Cys Arg Pro Ser Glu Asp Ile Phe Asn Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Asn Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Tyr Ser Leu Met Ile Ile Arg Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Val Ala Ser Tyr Phe Cys His Gln Tyr Asn Ile Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  257
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "6D6-B8" anti-CD123 antibody

<400>  257

Glu Asp Ile Phe Asn Asn 
1               5       


<210>  258
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "6D6-B8" anti-CD123 antibody

<400>  258

His Gln Tyr Asn Ile Tyr Pro Tyr Thr 
1               5                   


<210>  259
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "8B11-B7" anti-CD123 antibody.

<400>  259

Gln Val Gln Leu Gln Glu Ser Gly Pro Thr Leu Val Asn Pro Gly Asp 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 
            20                  25                  30          


Ile Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Ser Gly Gly Ala Asn Tyr Asn Gly Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Ile Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Phe Ser Arg Leu Thr Ser Gly Asp Ser Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  260
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "8B11-B7" anti-CD123 antibody

<400>  260

Ile Asn Pro Tyr Ser Gly Gly Ala 
1               5               


<210>  261
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called  "8B11-B7" anti-CD123 antibody

<400>  261

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Glu Cys Arg Thr Ser Lys Asp Ile Tyr Ser Asn 
            20                  25                  30          


Leu Ala Trp Phe Gln Gln Glu Pro Gly Asn Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Tyr Ser Leu Gln Ile Asn Asn Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Val Ala Ser Tyr Phe Cys His Gln Tyr Asn Asn Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  262
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called  "8B11-B7" anti-CD123 antibody

<400>  262

Lys Asp Ile Tyr Ser Asn 
1               5       


<210>  263
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called  "8B11-B7" anti-CD123 antibody

<400>  263

His Gln Tyr Asn Asn Tyr Pro Tyr Thr 
1               5                   


<210>  264
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "9B8-G6" anti-CD123 antibody

<400>  264

Glu Val Lys Leu Gln Glu Ser Gly Pro Ser Leu Val Gln Ser Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


His Ile His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Val Met Trp Ser Asp Gly Asp Thr Ser Tyr Ser Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Gln Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Asp Tyr Ser Ser Tyr Ile Tyr Leu Trp Phe Ala Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  265
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "9B8-G6" and "9D7-C8" anti-CD123 
       antibodies

<400>  265

Gly Phe Ser Leu Thr Ser Tyr His 
1               5               


<210>  266
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "9B8-G6" and "9D7-C8" anti-CD123 
       antibodies

<400>  266

Met Trp Ser Asp Gly Asp Thr 
1               5           


<210>  267
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "9B8-G6" anti-CD123 antibody

<400>  267

Ala Arg Gly Asp Tyr Ser Ser Tyr Ile Tyr Leu Trp Phe Ala Tyr 
1               5                   10                  15  


<210>  268
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "9D7-C8" anti-CD123 antibody

<400>  268

Glu Val Lys Leu Gln Glu Ser Gly Pro Ser Leu Val Gln Ser Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


His Ile His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Val Met Trp Ser Asp Gly Asp Thr Ser Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Gln Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Tyr Tyr Ser Ser Tyr Leu Tyr Leu Trp Phe Ala Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  269
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "9D7-C8" anti-CD123 antibody

<400>  269

Ala Arg Gly Tyr Tyr Ser Ser Tyr Leu Tyr Leu Trp Phe Ala Tyr 
1               5                   10                  15  


<210>  270
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "9D7-C8" anti-CD123 antibody

<400>  270

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Glu Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Phe Leu Ser Ser 
            20                  25                  30          


Gly Asp Gly Lys Asn Tyr Val Ala Trp Tyr Gln Tyr Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gln Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Ile Tyr Tyr Cys Gln Gln 
                85                  90                  95      


Tyr Tyr Asp Thr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  271
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "9D7-C8" anti-CD123 antibody

<400>  271

Gln Ser Phe Leu Ser Ser Gly Asp Gly Lys Asn Tyr 
1               5                   10          


<210>  272
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of the so-called "9F6-G3" anti-CD123 antibody

<400>  272

Gln Val Gln Leu Gln Glu Ser Gly Pro Thr Leu Val Lys Pro Gly Asp 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Ile Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Ser Asp Gly Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Phe Ser Arg Leu Thr Ser Glu Asp Ser Ala Ile Tyr Phe Cys 
                85                  90                  95      


Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Val Thr Val Ser Ser 
        115                 


<210>  273
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "9F6-G3" anti-CD123 antibody

<400>  273

Gly Tyr Thr Phe Thr Asp Tyr Ile 
1               5               


<210>  274
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "9F6-G3" anti-CD123 antibody

<400>  274

Ile Asn Pro Tyr Ser Asp Gly Thr 
1               5               


<210>  275
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of the so-called "9F6-G3" anti-CD123 antibody

<400>  275

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Glu Cys Arg Pro Ser Glu Asp Ile His Ser Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Val Ala Ser Tyr Phe Cys His Gln Tyr Asn Ile Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  276
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "9F6-G3" anti-CD123 antibody

<400>  276

Glu Asp Ile His Ser Asn 
1               5       


<210>  277
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH_G45A of humanized "3E3" anti-CD123 antibody

<400>  277

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ile Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Val Gln Thr Glu Asp Thr Ala Met Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  278
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VHmDG variant of "3E3" anti-CD123 antibody

<400>  278

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asp Gly Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ile Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Val Gln Thr Glu Asp Thr Ala Met Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  279
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of  VHmDG variant of "3E3" and CDR2H of humanized "3E3" 
       anti-CD123 antibody

<400>  279

Gln Asp Gly Gly Ile Thr 
1               5       


<210>  280
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1A of humanized "3E3" anti-CD123 antibody

<400>  280

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  281
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1B of humanized "3E3" anti-CD123 antibody

<400>  281

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  282
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1C of humanized "3E3" anti-CD123 antibody

<400>  282

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Val Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  283
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1D of humanized "3E3" anti-CD123 antibody

<400>  283

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Val Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  284
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1E of humanized "3E3" anti-CD123 antibody

<400>  284

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  285
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1F of humanized "3E3" anti-CD123 antibody

<400>  285

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  286
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1G of humanized "3E3" anti-CD123 antibody

<400>  286

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Gln Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  287
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1Fm1 of humanized "3E3" anti-CD123 antibody

<400>  287

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  288
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1Fm2 of humanized "3E3" anti-CD123 antibody

<400>  288

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Ser Leu 
65                  70                  75                  80  


Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  289
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1Fm2DG of humanized "3E3" anti-CD123 antibody

<400>  289

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asp Gly Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Ser Leu 
65                  70                  75                  80  


Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  290
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1Dm1 of humanized "3E3" anti-CD123 antibody

<400>  290

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Val Ser Leu 
65                  70                  75                  80  


Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  291
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1Em1 of humanized "3E3" anti-CD123 antibody

<400>  291

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Ser Leu 
65                  70                  75                  80  


Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  292
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1A of humanized "3E3" anti-CD123 antibody

<400>  292

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  293
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1B of humanized "3E3" anti-CD123 antibody

<400>  293

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  294
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1C of humanized "3E3" anti-CD123 antibody

<400>  294

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  295
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1D of humanized "3E3" anti-CD123 antibody

<400>  295

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln His Pro Gly Ser Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  296
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1E of humanized "3E3" anti-CD123 antibody

<400>  296

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Ser Pro Gly Ser 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  297
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1F of humanized "3E3" anti-CD123 antibody

<400>  297

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Ser Pro Gly Ser 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Val Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  298
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1G of humanized "3E3" anti-CD123 antibody

<400>  298

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Ser Pro Gly Ser 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln His Pro Gly Ser Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Val Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  299
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1Fm1 of humanized "3E3" anti-CD123 antibody

<400>  299

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Ser Pro Gly Ser 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Val Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  300
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1Fm2 of humanized "3E3" anti-CD123 antibody

<400>  300

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Ser Pro Gly Ser 
1               5                   10                  15      


Thr Val Thr Leu Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Val Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  301
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH2A of humanized "3E3" anti-CD123 antibody

<400>  301

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ile Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Val Thr Thr Ala Asp Thr Ala Met Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  302
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH3A of humanized "3E3" anti-CD123 antibody

<400>  302

Gln Val Thr Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 
            20                  25                  30          


Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ile Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Val Asp Thr Val Asp Thr Ala Met Tyr Phe Cys Ala 
                85                  90                  95      


Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  303
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2A of humanized "3E3" anti-CD123 antibody.

<400>  303

Gln Phe Val Leu Thr Gln Pro Pro Ser Val Ser Thr Asn Pro Gly Ser 
1               5                   10                  15      


Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn 
65                  70                  75                  80  


Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  304
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2Am1 of humanized "3E3" anti-CD123 antibody

<400>  304

Gln Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Asn Pro Gly Ser 
1               5                   10                  15      


Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn 
65                  70                  75                  80  


Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  305
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL2Am2 of humanized "3E3" anti-CD123 antibody.

<400>  305

Gln Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Asn Pro Gly Ser 
1               5                   10                  15      


Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn 
65                  70                  75                  80  


Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110     


<210>  306
<211>  344
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide I of the so-called CODV-Fab "7G3 x 20G6" 
       antibody-like binding protein

<400>  306

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Asp Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


Gly Gln Pro Lys Ala Ala Pro Asp Phe Val Met Thr Gln Ser Pro Ser 
        115                 120                 125             


Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser 
    130                 135                 140                 


Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp 
145                 150                 155                 160 


Tyr Leu Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala 
                165                 170                 175     


Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 
            180                 185                 190         


Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu 
        195                 200                 205             


Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly 
    210                 215                 220                 


Gly Gly Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val 
225                 230                 235                 240 


Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 
                245                 250                 255     


Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 
            260                 265                 270         


Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 
        275                 280                 285             


Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 
    290                 295                 300                 


Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 
305                 310                 315                 320 


Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 
                325                 330                 335     


Lys Ser Phe Asn Arg Gly Glu Cys 
            340                 


<210>  307
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  L1 of the so-called CODV-Fab "7G3x20G6", "7G3x4E7", "7G3x4B4", 
       "7G3x18F5", "hz20G6x7G3", "7G3xhz4B4", "hz4B4x3E3" and CODV-Fab 
       "hz20G6x7G3-TL4" antibody-like binding proteins

<400>  307

Gly Gln Pro Lys Ala Ala Pro 
1               5           


<210>  308
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL1 or VL2 domain of the so-called CODV-Fab "7G3x20G6", 
       "7G3x4E7", "7G3x4B4", "7G3x18F5", "hz20G6x7G3", "7G3xhz4B4" and 
       CODV-Fab "hz20G6x7G3-TL4" antibody-like binding proteins

<400>  308

Asp Phe Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Leu Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  309
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  L2 of the so-called CODV-Fab "7G3x20G6", "7G3x4E7", "7G3x4B4", 
       "7G3x18F5", "hz20G6x7G3", "7G3xhz4B4", "hz4B4x3E3" and CODV-Fab 
       "hz20G6x7G3-TL4" antibody-like binding proteins

<400>  309

Thr Lys Gly Pro Ser 
1               5   


<210>  310
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CL of the so-called CODV-Fab "7G3x20G6", "7G3x4E7", "7G3x4B4", 
       "7G3x18F5", "hz20G6x7G3", "7G3xhz4B4" and "hz4B4x3E3" 
       antibody-like binding proteins

<400>  310

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
1               5                   10                  15      


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
            20                  25                  30          


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
        35                  40                  45              


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
65                  70                  75                  80  


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
                85                  90                  95      


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            100                 105         


<210>  311
<211>  342
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide II of the so-called CODV-Fab "7G3 x 20G6" 
       antibody-like binding protein

<400>  311

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala Ser Glu Val Gln Leu Val Glu Thr 
        115                 120                 125             


Gly Gly Ser Leu Val Gln Pro Gly Lys Ser Leu Lys Leu Thr Cys Ala 
    130                 135                 140                 


Thr Ser Gly Phe Thr Phe Thr Lys Ala Trp Met His Trp Val Arg Gln 
145                 150                 155                 160 


Ser Pro Glu Lys Gln Leu Glu Trp Val Ala Gln Ile Lys Asp Lys Ser 
                165                 170                 175     


Asn Ser Tyr Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr 
            180                 185                 190         


Ile Ser Arg Asp Asp Ser Lys Ser Thr Ile Tyr Leu Gln Met Asn Ser 
        195                 200                 205             


Leu Lys Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Gly Val Tyr Tyr 
    210                 215                 220                 


Ala Leu Ser Pro Phe Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val 
225                 230                 235                 240 


Ser Ser Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
                245                 250                 255     


Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 
            260                 265                 270         


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
        275                 280                 285             


Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 
    290                 295                 300                 


Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 
305                 310                 315                 320 


Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 
                325                 330                 335     


Lys Val Asp Lys Lys Val 
            340         


<210>  312
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH1 or VH2 domain of the so-called CODV-Fab "7G3x20G6", 
       "7G3x4E7", "7G3x4B4", "7G3x18F5", "hz20G6x7G3", "7G3xhz4B4" and 
       CODV-Fab "hz20G6x7G3-TL4" antibody-like binding proteins

<400>  312

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala 
        115                 120 


<210>  313
<211>  98
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CH1 of the so-called CODV-Fab "7G3x20G6", "7G3x4E7", "7G3x4B4", 
       "7G3x18F5", "hz20G6x7G3", "7G3xhz4B4", "hz4B4x3E3" antibody-like 
       binding proteins

<400>  313

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val 
        


<210>  314
<211>  344
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide I of the so-called CODV-Fab "7G3 x 4E7" antibody-like
       binding protein

<400>  314

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu His Asn 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


Gly Gln Pro Lys Ala Ala Pro Asp Phe Val Met Thr Gln Ser Pro Ser 
        115                 120                 125             


Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser 
    130                 135                 140                 


Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp 
145                 150                 155                 160 


Tyr Leu Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala 
                165                 170                 175     


Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 
            180                 185                 190         


Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu 
        195                 200                 205             


Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly 
    210                 215                 220                 


Gly Gly Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val 
225                 230                 235                 240 


Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 
                245                 250                 255     


Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 
            260                 265                 270         


Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 
        275                 280                 285             


Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 
    290                 295                 300                 


Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 
305                 310                 315                 320 


Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 
                325                 330                 335     


Lys Ser Phe Asn Arg Gly Glu Cys 
            340                 


<210>  315
<211>  343
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide II of the so-called CODV-Fab "7G3 x 4E7" 
       antibody-like binding protein

<400>  315

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala Ser Glu Val Gln Val Val Glu Thr 
        115                 120                 125             


Gly Gly Ser Leu Val Gln Pro Gly Lys Ser Leu Lys Leu Thr Cys Ala 
    130                 135                 140                 


Thr Ser Gly Phe Thr Phe Ser Asn Ala Trp Met His Trp Val Arg Gln 
145                 150                 155                 160 


Ser Pro Glu Lys Gln Leu Glu Trp Val Ala Gln Ile Lys Asp Lys Ser 
                165                 170                 175     


Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Leu Lys Gly Arg Phe Thr 
            180                 185                 190         


Ile Ser Arg Asp Asp Pro Lys Arg Ser Ile Tyr Leu Gln Met Asn Ser 
        195                 200                 205             


Leu Arg Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Tyr Val His Tyr 
    210                 215                 220                 


Gly Ile Gly Tyr Ala Met Asp Ala Trp Gly Gln Gly Thr Ser Val Thr 
225                 230                 235                 240 


Val Ser Ser Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 
                245                 250                 255     


Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 
            260                 265                 270         


Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 
        275                 280                 285             


Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 
    290                 295                 300                 


Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 
305                 310                 315                 320 


Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 
                325                 330                 335     


Thr Lys Val Asp Lys Lys Val 
            340             


<210>  316
<211>  344
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide I of the so-called CODV-Fab "7G3 x 4B4" antibody-like
       binding protein

<400>  316

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Thr Ser 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


Gly Gln Pro Lys Ala Ala Pro Asp Phe Val Met Thr Gln Ser Pro Ser 
        115                 120                 125             


Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser 
    130                 135                 140                 


Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp 
145                 150                 155                 160 


Tyr Leu Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala 
                165                 170                 175     


Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 
            180                 185                 190         


Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu 
        195                 200                 205             


Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly 
    210                 215                 220                 


Gly Gly Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val 
225                 230                 235                 240 


Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 
                245                 250                 255     


Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 
            260                 265                 270         


Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 
        275                 280                 285             


Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 
    290                 295                 300                 


Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 
305                 310                 315                 320 


Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 
                325                 330                 335     


Lys Ser Phe Asn Arg Gly Glu Cys 
            340                 


<210>  317
<211>  342
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide II of the so-called CODV-Fab "7G3 x 4B4" 
       antibody-like binding protein

<400>  317

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala Ser Glu Val Gln Leu Val Glu Thr 
        115                 120                 125             


Gly Gly Arg Leu Val Gln Pro Gly Arg Ser Leu Lys Leu Thr Cys Ala 
    130                 135                 140                 


Thr Ser Gly Phe Thr Phe Ser Asn Ala Trp Met His Trp Val Arg Gln 
145                 150                 155                 160 


Ser Pro Glu Lys Gln Leu Glu Trp Val Ala Gln Ile Lys Ala Arg Ser 
                165                 170                 175     


Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr 
            180                 185                 190         


Ile Ser Arg Asp Asp Ser Lys Ser Thr Ile Tyr Leu Gln Met Asn Ser 
        195                 200                 205             


Leu Lys Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Gly Thr Tyr Tyr 
    210                 215                 220                 


Ala Ser Lys Pro Phe Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val 
225                 230                 235                 240 


Ser Ser Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
                245                 250                 255     


Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 
            260                 265                 270         


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
        275                 280                 285             


Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 
    290                 295                 300                 


Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 
305                 310                 315                 320 


Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 
                325                 330                 335     


Lys Val Asp Lys Lys Val 
            340         


<210>  318
<211>  344
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide I of the so-called CODV-Fab "7G3x18F5" antibody-like 
       binding protein.

<400>  318

Asp Val Leu Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Thr 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Ser Gly Ile Ser 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr His Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105                 110         


Gly Gln Pro Lys Ala Ala Pro Asp Phe Val Met Thr Gln Ser Pro Ser 
        115                 120                 125             


Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser 
    130                 135                 140                 


Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp 
145                 150                 155                 160 


Tyr Leu Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala 
                165                 170                 175     


Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 
            180                 185                 190         


Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu 
        195                 200                 205             


Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly 
    210                 215                 220                 


Gly Gly Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val 
225                 230                 235                 240 


Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 
                245                 250                 255     


Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 
            260                 265                 270         


Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 
        275                 280                 285             


Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 
    290                 295                 300                 


Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 
305                 310                 315                 320 


Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 
                325                 330                 335     


Lys Ser Phe Asn Arg Gly Glu Cys 
            340                 


<210>  319
<211>  343
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide II of the so-called CODV-Fab "7G3x18F5" antibody-like
       binding protein.

<400>  319

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala Ser Glu Val Gln Val Val Glu Thr 
        115                 120                 125             


Gly Gly Ser Leu Val Gln Pro Gly Lys Ser Leu Lys Leu Thr Cys Ala 
    130                 135                 140                 


Thr Ser Gly Phe Thr Phe Thr Asn Ala Trp Met His Trp Val Arg Arg 
145                 150                 155                 160 


Ser Pro Glu Lys Gln Leu Glu Trp Val Ala Gln Ile Lys Asp Lys Ser 
                165                 170                 175     


Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr 
            180                 185                 190         


Ile Ser Arg Asp Asp Ser Lys Ser Ser Ile Tyr Leu Gln Met Asn Ser 
        195                 200                 205             


Leu Lys Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Tyr Val His Tyr 
    210                 215                 220                 


Arg Phe Ala Tyr Ala Leu Asp Ala Trp Gly Arg Gly Thr Ser Val Ser 
225                 230                 235                 240 


Val Ser Ser Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 
                245                 250                 255     


Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 
            260                 265                 270         


Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 
        275                 280                 285             


Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 
    290                 295                 300                 


Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 
305                 310                 315                 320 


Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 
                325                 330                 335     


Thr Lys Val Asp Lys Lys Val 
            340             


<210>  320
<211>  344
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide I of the so-called CODV-Fab "hz20G6 x 7G3" 
       antibody-like binding protein

<400>  320

Asp Phe Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Leu Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys Gly Gln Pro Lys Ala Ala Pro Asp Ile Val Met Thr Gln Thr Pro 
        115                 120                 125             


Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr Leu Ser Trp 
145                 150                 155                 160 


Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Ser Leu Ile Tyr Lys Val 
                165                 170                 175     


Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser 
            180                 185                 190         


Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val 
        195                 200                 205             


Gly Val Tyr Tyr Cys Gly Gln Gly Thr Gln Tyr Pro Phe Thr Phe Gly 
    210                 215                 220                 


Ser Gly Thr Lys Val Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val 
225                 230                 235                 240 


Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 
                245                 250                 255     


Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 
            260                 265                 270         


Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 
        275                 280                 285             


Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 
    290                 295                 300                 


Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 
305                 310                 315                 320 


Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 
                325                 330                 335     


Lys Ser Phe Asn Arg Gly Glu Cys 
            340                 


<210>  321
<211>  342
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide II of the so-called CODV-Fab "hz20G6 x 7G3" 
       antibody-like binding protein

<400>  321

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Ser Glu Val Gln Leu Gln Gln 
        115                 120                 125             


Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys 
    130                 135                 140                 


Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Lys Trp Val Lys 
145                 150                 155                 160 


Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Ile Pro Ser 
                165                 170                 175     


Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu 
            180                 185                 190         


Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr Met His Leu Asn Ser Leu 
        195                 200                 205             


Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Ser His Leu Leu 
    210                 215                 220                 


Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 
225                 230                 235                 240 


Ser Ala Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
                245                 250                 255     


Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 
            260                 265                 270         


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
        275                 280                 285             


Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 
    290                 295                 300                 


Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 
305                 310                 315                 320 


Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 
                325                 330                 335     


Lys Val Asp Lys Lys Val 
            340         


<210>  322
<211>  344
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide I of the so-called CODV-Fab 7G3 x hz4B4" 
       antibody-like binding protein

<400>  322

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Val Gly 
1               5                   10                  15      


Gly Arg Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Lys Ser 
        35                  40                  45              


Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Ser 
    50                  55                  60                  


Ser Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Ser Val Gln Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly 
                85                  90                  95      


Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


Gly Gln Pro Lys Ala Ala Pro Asp Phe Val Met Thr Gln Ser Pro Ser 
        115                 120                 125             


Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser 
    130                 135                 140                 


Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp 
145                 150                 155                 160 


Tyr Leu Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala 
                165                 170                 175     


Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 
            180                 185                 190         


Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu 
        195                 200                 205             


Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly 
    210                 215                 220                 


Gly Gly Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val 
225                 230                 235                 240 


Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 
                245                 250                 255     


Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 
            260                 265                 270         


Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 
        275                 280                 285             


Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 
    290                 295                 300                 


Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 
305                 310                 315                 320 


Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 
                325                 330                 335     


Lys Ser Phe Asn Arg Gly Glu Cys 
            340                 


<210>  323
<211>  342
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide II of the so-called CODV-Fab "7G3 x hz4B4" 
       antibody-like binding protein

<400>  323

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ala Ser Gln Val Gln Leu Val Glu Thr 
        115                 120                 125             


Gly Gly Gly Leu Val Lys Pro Gly Gln Ser Leu Lys Leu Thr Cys Ala 
    130                 135                 140                 


Thr Ser Gly Phe Thr Phe Ser Asn Ala Trp Met His Trp Val Arg Gln 
145                 150                 155                 160 


Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Lys Ala Arg Ser 
                165                 170                 175     


Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr 
            180                 185                 190         


Ile Ser Arg Asp Asp Ser Lys Ser Thr Ile Tyr Leu Gln Met Asn Ser 
        195                 200                 205             


Leu Thr Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Gly Thr Tyr Tyr 
    210                 215                 220                 


Ala Ser Lys Pro Phe Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val 
225                 230                 235                 240 


Ser Ser Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
                245                 250                 255     


Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 
            260                 265                 270         


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
        275                 280                 285             


Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 
    290                 295                 300                 


Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 
305                 310                 315                 320 


Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 
                325                 330                 335     


Lys Val Asp Lys Lys Val 
            340         


<210>  324
<211>  342
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide I of the so-called CODV-Fab "hz4B4 x 3E3" 
       antibody-like binding protein

<400>  324

Gln Phe Val Leu Thr Gln Pro Asn Ser Val Ser Thr Asn Leu Gly Ser 
1               5                   10                  15      


Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln His Glu Gly Arg Ser Pro Thr Thr Met 
        35                  40                  45              


Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn 
65                  70                  75                  80  


Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser 
                85                  90                  95      


Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 
            100                 105                 110         


Gln Pro Lys Ala Ala Pro Asp Val Val Met Thr Gln Thr Pro Val Ser 
        115                 120                 125             


Leu Ser Val Ser Val Gly Gly Arg Val Ser Ile Ser Cys Arg Ser Ser 
    130                 135                 140                 


Gln Ser Leu Val His Asp Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu 
145                 150                 155                 160 


Gln Lys Pro Gly Lys Ser Pro Lys Val Leu Ile Tyr Lys Val Ser Asn 
                165                 170                 175     


Arg Phe Ser Gly Val Ser Ser Arg Phe Thr Gly Ser Gly Ser Gly Thr 
            180                 185                 190         


Asp Phe Thr Leu Lys Ile Ser Ser Val Gln Pro Asp Asp Leu Gly Val 
        195                 200                 205             


Tyr Tyr Cys Gly Gln Gly Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly 
    210                 215                 220                 


Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val Ala Ala 
225                 230                 235                 240 


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
                245                 250                 255     


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
            260                 265                 270         


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
        275                 280                 285             


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
    290                 295                 300                 


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
305                 310                 315                 320 


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
                325                 330                 335     


Phe Asn Arg Gly Glu Cys 
            340         


<210>  325
<211>  340
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide II of the so-called CODV-Fab "hz4B4 x 3E3" 
       antibody-like binding protein

<400>  325

Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Lys Pro Gly Gln 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr 
65                  70                  75                  80  


Ile Tyr Leu Gln Met Asn Ser Leu Thr Pro Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Val Met Val Thr Val Ser Ser Ser Gln Val Gln Leu Gln Glu 
        115                 120                 125             


Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Thr Leu Ser Leu Thr Cys 
    130                 135                 140                 


Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr Asp Val His Trp Val Arg 
145                 150                 155                 160 


Gln Pro Pro Gly Lys Gly Leu Glu Trp Met Gly Arg Ile Gln Asn Gly 
                165                 170                 175     


Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ile Ile Ser 
            180                 185                 190         


Arg Asp Thr Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Val Gln 
        195                 200                 205             


Thr Glu Asp Thr Ala Met Tyr Phe Cys Ala Lys Thr Gly Ser Tyr Phe 
    210                 215                 220                 


Tyr Ala Phe Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
225                 230                 235                 240 


Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 
                245                 250                 255     


Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 
            260                 265                 270         


Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 
        275                 280                 285             


Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 
    290                 295                 300                 


Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 
305                 310                 315                 320 


Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 
                325                 330                 335     


Asp Lys Lys Val 
            340 


<210>  326
<211>  572
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide I of the so-called CODV-Fab "hz20G6 x 7G3 TL4" 
       antibody-like binding protein

<400>  326

Asp Phe Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Leu Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys Gly Gln Pro Lys Ala Ala Pro Asp Ile Val Met Thr Gln Thr Pro 
        115                 120                 125             


Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys 
    130                 135                 140                 


Ser Ser Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr Leu Ser Trp 
145                 150                 155                 160 


Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Ser Leu Ile Tyr Lys Val 
                165                 170                 175     


Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser 
            180                 185                 190         


Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val 
        195                 200                 205             


Gly Val Tyr Tyr Cys Gly Gln Gly Thr Gln Tyr Pro Phe Thr Phe Gly 
    210                 215                 220                 


Ser Gly Thr Lys Val Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val 
225                 230                 235                 240 


Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 
                245                 250                 255     


Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 
            260                 265                 270         


Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn 
        275                 280                 285             


Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 
    290                 295                 300                 


Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 
305                 310                 315                 320 


Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 
                325                 330                 335     


Lys Ser Phe Asn Arg Gly Glu Cys Glu Ser Lys Tyr Gly Pro Pro Cys 
            340                 345                 350         


Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu 
        355                 360                 365             


Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 
    370                 375                 380                 


Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln 
385                 390                 395                 400 


Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 
                405                 410                 415     


Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu 
            420                 425                 430         


Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 
        435                 440                 445             


Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys 
    450                 455                 460                 


Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 
465                 470                 475                 480 


Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 
                485                 490                 495     


Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 
            500                 505                 510         


Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 
        515                 520                 525             


Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln 
    530                 535                 540                 


Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 
545                 550                 555                 560 


Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 
                565                 570         


<210>  327
<211>  228
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence Fc2 of the so-called CODV-Fab 
       "hz20G6x7G3-TL4" antibody-like binding protein

<400>  327

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 
1               5                   10                  15      


Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 
            20                  25                  30          


Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 
        35                  40                  45              


Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 
    50                  55                  60                  


Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 
65                  70                  75                  80  


Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 
                85                  90                  95      


Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 
            100                 105                 110         


Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 
        115                 120                 125             


Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 
    130                 135                 140                 


Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 
145                 150                 155                 160 


Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 
                165                 170                 175     


Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 
            180                 185                 190         


Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 
        195                 200                 205             


Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser 
    210                 215                 220                 


Leu Ser Leu Gly 
225             


<210>  328
<211>  570
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide III of the so-called CODV-Fab "hz20G6 x 7G3 TL4" 
       antibody-like binding protein

<400>  328

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Ser Glu Val Gln Leu Gln Gln 
        115                 120                 125             


Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys 
    130                 135                 140                 


Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Lys Trp Val Lys 
145                 150                 155                 160 


Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Ile Pro Ser 
                165                 170                 175     


Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu 
            180                 185                 190         


Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr Met His Leu Asn Ser Leu 
        195                 200                 205             


Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Ser His Leu Leu 
    210                 215                 220                 


Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 
225                 230                 235                 240 


Ser Ala Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
                245                 250                 255     


Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu 
            260                 265                 270         


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 
        275                 280                 285             


Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 
    290                 295                 300                 


Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 
305                 310                 315                 320 


Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr 
                325                 330                 335     


Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro 
            340                 345                 350         


Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro 
        355                 360                 365             


Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 
    370                 375                 380                 


Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn 
385                 390                 395                 400 


Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 
                405                 410                 415     


Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 
            420                 425                 430         


Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 
        435                 440                 445             


Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys 
    450                 455                 460                 


Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu 
465                 470                 475                 480 


Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 
                485                 490                 495     


Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 
            500                 505                 510         


Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 
        515                 520                 525             


Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly 
    530                 535                 540                 


Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 
545                 550                 555                 560 


Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 
                565                 570 


<210>  329
<211>  97
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CH1 of the so-called CODV-Fab "hz20G6x7G3-TL4"antibody-like 
       binding protein

<400>  329

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 
1               5                   10                  15      


Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 
65                  70                  75                  80  


Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Arg 
    


<210>  330
<211>  229
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fc of the so-called CODV-Fab "hz20G6x7G3-TL4"antibody-like 
       binding protein

<400>  330

Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu 
1               5                   10                  15      


Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 
            20                  25                  30          


Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 
        35                  40                  45              


Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly 
    50                  55                  60                  


Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn 
65                  70                  75                  80  


Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 
                85                  90                  95      


Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro 
            100                 105                 110         


Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 
        115                 120                 125             


Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn 
    130                 135                 140                 


Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 
145                 150                 155                 160 


Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 
                165                 170                 175     


Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg 
            180                 185                 190         


Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys 
        195                 200                 205             


Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 
    210                 215                 220                 


Ser Leu Ser Leu Gly 
225                 


<210>  331
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Consensus sequence  CDR1-H of anti-CD3 antibodies


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is T or S

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is F or V

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is S or T

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is N, K, L or Y

<400>  331

Gly Phe Xaa Xaa Xaa Xaa Ala Trp 
1               5               


<210>  332
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Consensus sequence for CDR2-H of anti-CD3 antibodies


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is A or D

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is K or R

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is S or A

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is N or S

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is A or E

<400>  332

Ile Lys Xaa Xaa Xaa Asn Xaa Tyr Xaa Thr 
1               5                   10  


<210>  333
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Consensus sequence for CDRF-H of anti-CD3 antibodies


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Y or G

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Y, G or A

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is V, T or L

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is H, N, Y or Q

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is G, R or A

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is F or V or no amino acid

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is R or no amino acid

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is F, S or I or no amino acid

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is F, L, N, M, Y, S, A or G

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is  Y, A, K, S, N, T, F or L

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa is  A, P, G or T

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa is  M, L, F or S

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Xaa is A, V, Y or G

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Xaa is A, V or Y

<400>  333

Arg Xaa Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa 
1               5                   10                  15  


<210>  334
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Consensus sequence for CDR1-L of anti-CD3 antibodies


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is R or S

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is V or E

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is N, D or T

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is N or Y

<400>  334

Gln Xaa Leu Xaa His Xaa Asn Gly Xaa Thr Tyr 
1               5                   10      


<210>  335
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  consensus sequence for CDR3-L of anti-CD3 antibodies


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is T, A or S

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is H, E or Q

<400>  335

Gly Gln Gly Xaa Xaa Tyr Pro Phe Thr 
1               5                   


<210>  336
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Consensus sequence for CDR1-H of the so-called "1E1-G5", 
       "6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is G or A

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is H, Y or N

<400>  336

Xaa Tyr Thr Phe Thr Asp Xaa Ile 
1               5               


<210>  337
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  consensus sequence for CDR2-H of the so-called "1E1-G5", 
       "6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is G or D

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is T or A

<400>  337

Ile Asn Pro Tyr Ser Xaa Gly Xaa 
1               5               


<210>  338
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  consensus sequence for CDR1-L of the so-called "1E1-G5", 
       "6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is E or K

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is F, H or Y

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is N or S

<400>  338

Xaa Asp Ile Xaa Xaa Asn 
1               5       


<210>  339
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  consensus sequence for CDR3-L of the so-called "1E1-G5", 
       "6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is H or Q

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is I, K or N

<400>  339

Xaa Gln Tyr Asn Xaa Tyr Pro Tyr Thr 
1               5                   


<210>  340
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  consensus sequence for CDR1-H of the so-called "6C10-C4", 
       9B8-G6", "9D7-C8" anti-CD123 antibodies


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is H or S

<400>  340

Gly Phe Ser Leu Thr Ser Tyr Xaa 
1               5               


<210>  341
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Consensus sequence for CDR2-H of the so-called "1E1-G5", 
       "6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be any naturally occurring amino acid

<400>  341

Met Trp Xaa Asp Gly Asp Thr 
1               5           


<210>  342
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  consensus sequence for CDR3-H of the so-called "1E1-G5", 
       "6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is D, Y or H

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is Y or R

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is S or T

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is S or P

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is Y or no amino acid

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is L, I or no amino acid

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is Y or no amino acid

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is L or no amino acid

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa s W or no amino acid

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is A or D

<400>  342

Ala Arg Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Tyr 
1               5                   10                  15  


<210>  343
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Consensus sequence for CDR1-L of "1E1-G5", "6D6-B8", 
       "8B11-B7","9F6-G3" anti-CD123 antibodies


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is E or G

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is R or K

<400>  343

Gln Ser Phe Leu Ser Ser Gly Asp Xaa Xaa Asn Tyr 
1               5                   10          


<210>  344
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  344

Gly Gly Gly Gly Ser 
1               5   


<210>  345
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  345

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10  


<210>  346
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  346

Thr Val Ala Ala Pro 
1               5   


<210>  347
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  347

Gln Pro Lys Ala Ala 
1               5   


<210>  348
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  348

Gln Arg Ile Glu Gly 
1               5   


<210>  349
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  349

Ala Ser Thr Lys Gly Pro Ser 
1               5           


<210>  350
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  350

Ala Ser Thr Lys Gly Pro Ser 
1               5           


<210>  351
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  351

His Ile Asp Ser Pro Asn Lys 
1               5           


<210>  352
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker and Histag sequence

<400>  352

Glu Pro Lys Ser Cys Asp Lys Thr His Thr His His His His His His 
1               5                   10                  15      


<210>  353
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H variant of the so-called "3E3" anti-CD123 antibody.

<400>  353

Ile Gln Asn Ala Gly Ile Thr 
1               5           


<210>  354
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  354

Gly Gly Gly Ser 
1               


<210>  355
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  shows the amino acid sequence of a linker sequence

<400>  355

Ser Gly Gly Gly Ser 
1               5   


<210>  356
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  356

Gly Ser Gly Gly Gly Gly Ser 
1               5           


<210>  357
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  357

Gly Gly Ser Gly Gly Gly Gly Ser 
1               5               


<210>  358
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  358

Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   


<210>  359
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  359

Lys Thr His Thr 
1               


<210>  360
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  360

Lys Thr His Thr Ser 
1               5   


<210>  361
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  361

Asp Lys Thr His Thr Ser 
1               5       


<210>  362
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  362

Asp Lys Thr His Thr Ser Pro 
1               5           


<210>  363
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  363

Ser Asp Lys Thr His Thr Ser Pro 
1               5               


<210>  364
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  364

Ser Asp Lys Thr His Thr Ser Pro Pro 
1               5                   


<210>  365
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  365

Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser 
1               5                   10      


<210>  366
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  366

Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser 
1               5                   10          


<210>  367
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  367

Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro 
1               5                   10              


<210>  368
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  368

Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro 
1               5                   10                  


<210>  369
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  the amino acid sequence of a linker sequence

<400>  369

Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Gly 
1               5                   10                  15  


<210>  370
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  370

Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Gly 
1               5                   10                  15      


<210>  371
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  371

Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Gly 
1               5                   10                  15      


Gly 
    


<210>  372
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  372

Gly Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro 
1               5                   10                  15      


Gly Gly 
        


<210>  373
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  373

Gly Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro 
1               5                   10                  15      


Gly Gly Gly 
            


<210>  374
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  amino acid sequence of a linker sequence

<400>  374

Gly Gly Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser 
1               5                   10                  15      


Pro Gly Gly Gly 
            20  


<210>  375
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called "7G3" antibody.

<400>  375

Gly Tyr Thr Phe Thr Asp Tyr Tyr 
1               5               


<210>  376
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of the so-called "7G3" antibody.

<400>  376

Ile Ile Pro Ser Asn Gly Ala Thr 
1               5               


<210>  377
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called "7G3" antibody.

<400>  377

Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr 
1               5                   10              


<210>  378
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-L of the so-called "7G3" antibody.

<400>  378

Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr 
1               5                   10          


<210>  379
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-L of the so-called "7G3" antibody.

<400>  379

Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr 
1               5                   


<210>  380
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH variant amino acid sequence of the so-called humanized "7G3" 
       antibody.

<400>  380

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Lys Trp Ala Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Thr Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  381
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1-H of the so-called humanized "7G3" antibody

<400>  381

Gly Tyr Ser Phe Thr Asp Tyr Tyr 
1               5               


<210>  382
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3-H of the so-called humanized "7G3" antibody.

<400>  382

Ala Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr 
1               5                   10              


<210>  383
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH varaint of the so-called humanized "7G3" antibody.

<400>  383

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Lys Trp Ala Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Asp Ile Ile Pro Ser Ser Gly Ala Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Thr Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Met Val Thr Val Ser Ser 
        115                 120 


<210>  384
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2-H of one of the so-called humanized "7G3" antibody.

<400>  384

Ile Ile Pro Ser Ser Gly Ala Thr 
1               5               


<210>  385
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL varaint of the so-called humanized "7G3" antibody.

<400>  385

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Glu Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Pro Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  386
<211>  272
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SEQ ID NO:1 of WO2015/026892

<400>  386

Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 
1               5                   10                  15      


Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 
            20                  25                  30          


Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly 
        35                  40                  45              


Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Thr Pro Ala Arg Phe 
    50                  55                  60                  


Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Thr Gly Ala 
65                  70                  75                  80  


Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn 
                85                  90                  95      


Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly 
            100                 105                 110         


Gly Ser Gly Gly Gly Gly Glu Val Gln Leu Val Gln Ser Gly Ala Glu 
        115                 120                 125             


Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly 
    130                 135                 140                 


Tyr Thr Phe Thr Asp Tyr Tyr Met Lys Trp Val Arg Gln Ala Pro Gly 
145                 150                 155                 160 


Gln Gly Leu Glu Trp Ile Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr 
                165                 170                 175     


Phe Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp Lys 
            180                 185                 190         


Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp 
        195                 200                 205             


Thr Ala Val Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg Ala Ser Trp 
    210                 215                 220                 


Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 
225                 230                 235                 240 


Cys Gly Gly Gly Glu Val Ala Ala Leu Glu Lys Glu Val Ala Ala Leu 
                245                 250                 255     


Glu Lys Glu Val Ala Ala Leu Glu Lys Glu Val Ala Ala Leu Glu Lys 
            260                 265                 270         


<210>  387
<211>  280
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SEQ ID NO:3 of WO2015/026892

<400>  387

Asp Phe Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys Gly Gly Gly Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser 
        115                 120                 125             


Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala 
    130                 135                 140                 


Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln 
145                 150                 155                 160 


Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr 
                165                 170                 175     


Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr 
            180                 185                 190         


Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser 
        195                 200                 205             


Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn 
    210                 215                 220                 


Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr 
225                 230                 235                 240 


Leu Val Thr Val Ser Ser Gly Gly Cys Gly Gly Gly Lys Val Ala Ala 
                245                 250                 255     


Leu Lys Glu Lys Val Ala Ala Leu Lys Glu Lys Val Ala Ala Leu Lys 
            260                 265                 270         


Glu Lys Val Ala Ala Leu Lys Glu 
        275                 280 


<210>  388
<211>  352
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide I of the so-called CODV-Fab "hz20G6xhz7G3", 
       CODV-Fab-OL1 "hz20G6xhz7G3" and CODV-Fab-OL1a "hz20G6xhz7G3" 
       antibody-like binding proteins

<400>  388

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Glu Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Pro Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys Gly Gly Ser Gly Ser Ser Gly Ser Gly Gly Asp Ile Val Met Thr 
        115                 120                 125             


Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile 
    130                 135                 140                 


Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn Asn Ala Asn Thr Tyr 
145                 150                 155                 160 


Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Ser Leu Ile 
                165                 170                 175     


Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly 
            180                 185                 190         


Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala 
        195                 200                 205             


Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly Thr Gln Tyr Pro Phe 
    210                 215                 220                 


Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Ser 
225                 230                 235                 240 


Ser Gly Ser Gly Gly Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe 
                245                 250                 255     


Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys 
            260                 265                 270         


Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val 
        275                 280                 285             


Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln 
    290                 295                 300                 


Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser 
305                 310                 315                 320 


Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His 
                325                 330                 335     


Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            340                 345                 350         


<210>  389
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Linker

<400>  389

Gly Gly Ser Gly Ser Ser Gly Ser Gly Gly 
1               5                   10  


<210>  390
<211>  339
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide II of the so-called CODV-Fab "hz20G6xhz7G3" 
       antibody-like binding protein

<400>  390

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Glu Val Gln Leu Val Gln Ser 
        115                 120                 125             


Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys 
    130                 135                 140                 


Gly Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Met Lys Trp Ala Arg Gln 
145                 150                 155                 160 


Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asp Ile Ile Pro Ser Ser 
                165                 170                 175     


Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Gln Val Thr Ile Ser 
            180                 185                 190         


Ala Asp Lys Ser Ile Ser Thr Thr Tyr Leu Gln Trp Ser Ser Leu Lys 
        195                 200                 205             


Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg 
    210                 215                 220                 


Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser 
225                 230                 235                 240 


Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 
                245                 250                 255     


Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 
            260                 265                 270         


Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 
        275                 280                 285             


Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 
    290                 295                 300                 


Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 
305                 310                 315                 320 


Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 
                325                 330                 335     


Lys Lys Val 
            


<210>  391
<211>  578
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide IV of the so-called CODV-Fab-TL1 "hz20G6xhz7G3" 
       antibody-like binding protein

<400>  391

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Glu Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Pro Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn 
                85                  90                  95      


Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys Gly Gly Ser Gly Ser Ser Gly Ser Gly Gly Asp Ile Val Met Thr 
        115                 120                 125             


Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile 
    130                 135                 140                 


Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn Asn Ala Asn Thr Tyr 
145                 150                 155                 160 


Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Ser Leu Ile 
                165                 170                 175     


Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly 
            180                 185                 190         


Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala 
        195                 200                 205             


Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly Thr Gln Tyr Pro Phe 
    210                 215                 220                 


Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Ser 
225                 230                 235                 240 


Ser Gly Ser Gly Gly Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe 
                245                 250                 255     


Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys 
            260                 265                 270         


Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val 
        275                 280                 285             


Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln 
    290                 295                 300                 


Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser 
305                 310                 315                 320 


Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His 
                325                 330                 335     


Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            340                 345                 350         


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 
        355                 360                 365             


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
    370                 375                 380                 


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
385                 390                 395                 400 


Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
                405                 410                 415     


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
            420                 425                 430         


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 
        435                 440                 445             


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 
    450                 455                 460                 


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 
465                 470                 475                 480 


Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 
                485                 490                 495     


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
            500                 505                 510         


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
        515                 520                 525             


Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 
    530                 535                 540                 


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 
545                 550                 555                 560 


His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser 
                565                 570                 575     


Pro Gly 
        


<210>  392
<211>  226
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fc2 of the so-called CODV-Fab-TL1 "hz20G6xhz7G3" antibody-like 
       binding protein

<400>  392

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 
1               5                   10                  15      


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 
            20                  25                  30          


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
        35                  40                  45              


Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
    50                  55                  60                  


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
65                  70                  75                  80  


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 
                85                  90                  95      


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 
            100                 105                 110         


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 
        115                 120                 125             


Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 
    130                 135                 140                 


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
145                 150                 155                 160 


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
                165                 170                 175     


Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 
            180                 185                 190         


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 
        195                 200                 205             


His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser 
    210                 215                 220                 


Pro Gly 
225     


<210>  393
<211>  570
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide III of the so-called CODV-Fab-TL1 "hz20G6xhz7G3" 
       antibody-like binding protein

<400>  393

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Glu Val Gln Leu Val Gln Ser 
        115                 120                 125             


Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys 
    130                 135                 140                 


Gly Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Met Lys Trp Ala Arg Gln 
145                 150                 155                 160 


Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asp Ile Ile Pro Ser Ser 
                165                 170                 175     


Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Gln Val Thr Ile Ser 
            180                 185                 190         


Ala Asp Lys Ser Ile Ser Thr Thr Tyr Leu Gln Trp Ser Ser Leu Lys 
        195                 200                 205             


Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg 
    210                 215                 220                 


Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser 
225                 230                 235                 240 


Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 
                245                 250                 255     


Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 
            260                 265                 270         


Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 
        275                 280                 285             


Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 
    290                 295                 300                 


Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 
305                 310                 315                 320 


Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 
                325                 330                 335     


Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 
            340                 345                 350         


Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro 
        355                 360                 365             


Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 
    370                 375                 380                 


Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 
385                 390                 395                 400 


Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 
                405                 410                 415     


Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 
            420                 425                 430         


Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 
        435                 440                 445             


Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 
    450                 455                 460                 


Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 
465                 470                 475                 480 


Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 
                485                 490                 495     


Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 
            500                 505                 510         


Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 
        515                 520                 525             


Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 
    530                 535                 540                 


Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 
545                 550                 555                 560 


Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 
                565                 570 


<210>  394
<211>  231
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fc region of the so-called CODV-Fab-TL1 "hz20G6xhz7G3" 
       antibody-like binding protein

<400>  394

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
1               5                   10                  15      


Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
            20                  25                  30          


Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
        35                  40                  45              


Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 
    50                  55                  60                  


Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
65                  70                  75                  80  


Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
                85                  90                  95      


Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 
            100                 105                 110         


Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
        115                 120                 125             


Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 
    130                 135                 140                 


Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 
145                 150                 155                 160 


Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
                165                 170                 175     


Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
            180                 185                 190         


Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 
        195                 200                 205             


Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
    210                 215                 220                 


Ser Leu Ser Leu Ser Pro Gly 
225                 230     


<210>  395
<211>  570
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide II of the so-called CODV-Fab-OL1 "hz20G6xhz7G3" 
       antibody-like binding protein

<400>  395

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Glu Val Gln Leu Val Gln Ser 
        115                 120                 125             


Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys 
    130                 135                 140                 


Gly Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Met Lys Trp Ala Arg Gln 
145                 150                 155                 160 


Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asp Ile Ile Pro Ser Ser 
                165                 170                 175     


Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Gln Val Thr Ile Ser 
            180                 185                 190         


Ala Asp Lys Ser Ile Ser Thr Thr Tyr Leu Gln Trp Ser Ser Leu Lys 
        195                 200                 205             


Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg 
    210                 215                 220                 


Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser 
225                 230                 235                 240 


Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 
                245                 250                 255     


Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 
            260                 265                 270         


Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 
        275                 280                 285             


Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 
    290                 295                 300                 


Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 
305                 310                 315                 320 


Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 
                325                 330                 335     


Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 
            340                 345                 350         


Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro 
        355                 360                 365             


Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 
    370                 375                 380                 


Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 
385                 390                 395                 400 


Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 
                405                 410                 415     


Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 
            420                 425                 430         


Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 
        435                 440                 445             


Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 
    450                 455                 460                 


Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp 
465                 470                 475                 480 


Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe 
                485                 490                 495     


Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 
            500                 505                 510         


Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 
        515                 520                 525             


Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 
    530                 535                 540                 


Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe 
545                 550                 555                 560 


Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 
                565                 570 


<210>  396
<211>  231
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fc region of the so-called CODV-Fab-OL1 "hz20G6xhz7G3" 
       antibody-like binding protein

<400>  396

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
1               5                   10                  15      


Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
            20                  25                  30          


Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
        35                  40                  45              


Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 
    50                  55                  60                  


Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
65                  70                  75                  80  


Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
                85                  90                  95      


Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 
            100                 105                 110         


Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
        115                 120                 125             


Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr 
    130                 135                 140                 


Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser 
145                 150                 155                 160 


Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
                165                 170                 175     


Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
            180                 185                 190         


Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 
        195                 200                 205             


Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys 
    210                 215                 220                 


Ser Leu Ser Leu Ser Pro Gly 
225                 230     


<210>  397
<211>  228
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fc3 of the so-called CODV-Fab-OL1 "hz20G6xhz7G3" antibody-like 
       binding protein

<400>  397

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala 
1               5                   10                  15      


Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 
            20                  25                  30          


Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 
        35                  40                  45              


Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 
    50                  55                  60                  


Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 
65                  70                  75                  80  


Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 
                85                  90                  95      


Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 
            100                 105                 110         


Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 
        115                 120                 125             


Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 
    130                 135                 140                 


Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 
145                 150                 155                 160 


Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 
                165                 170                 175     


Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu 
            180                 185                 190         


Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 
        195                 200                 205             


Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 
    210                 215                 220                 


Leu Ser Pro Gly 
225             


<210>  398
<211>  228
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fc3 of the so-called CODV-Fab-OL1a "hz20G6xhz7G3"

<400>  398

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala 
1               5                   10                  15      


Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 
            20                  25                  30          


Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 
        35                  40                  45              


Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 
    50                  55                  60                  


Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 
65                  70                  75                  80  


Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 
                85                  90                  95      


Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 
            100                 105                 110         


Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 
        115                 120                 125             


Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 
    130                 135                 140                 


Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 
145                 150                 155                 160 


Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 
                165                 170                 175     


Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu 
            180                 185                 190         


Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 
        195                 200                 205             


Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser 
    210                 215                 220                 


Leu Ser Pro Gly 
225             


<210>  399
<211>  570
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  polypeptide of formula II of the so-called CODV-Fab-OL1a  
       "hz20G6xhz7G3"

<400>  399

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val 
        35                  40                  45              


Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Glu Val Gln Leu Val Gln Ser 
        115                 120                 125             


Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys 
    130                 135                 140                 


Gly Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Met Lys Trp Ala Arg Gln 
145                 150                 155                 160 


Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asp Ile Ile Pro Ser Ser 
                165                 170                 175     


Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Gln Val Thr Ile Ser 
            180                 185                 190         


Ala Asp Lys Ser Ile Ser Thr Thr Tyr Leu Gln Trp Ser Ser Leu Lys 
        195                 200                 205             


Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg 
    210                 215                 220                 


Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser 
225                 230                 235                 240 


Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 
                245                 250                 255     


Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 
            260                 265                 270         


Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 
        275                 280                 285             


Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 
    290                 295                 300                 


Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 
305                 310                 315                 320 


Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 
                325                 330                 335     


Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 
            340                 345                 350         


Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro 
        355                 360                 365             


Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 
    370                 375                 380                 


Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 
385                 390                 395                 400 


Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 
                405                 410                 415     


Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 
            420                 425                 430         


Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 
        435                 440                 445             


Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 
    450                 455                 460                 


Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp 
465                 470                 475                 480 


Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe 
                485                 490                 495     


Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 
            500                 505                 510         


Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 
        515                 520                 525             


Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 
    530                 535                 540                 


Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 
545                 550                 555                 560 


Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 
                565                 570 


<210>  400
<211>  231
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fc3 of the so-called CODV-Fab-OL1a "hz20G6xhz7G3" antibody-like 
       binding protein

<400>  400

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
1               5                   10                  15      


Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
            20                  25                  30          


Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
        35                  40                  45              


Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 
    50                  55                  60                  


Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
65                  70                  75                  80  


Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
                85                  90                  95      


Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 
            100                 105                 110         


Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
        115                 120                 125             


Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr 
    130                 135                 140                 


Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser 
145                 150                 155                 160 


Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
                165                 170                 175     


Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
            180                 185                 190         


Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 
        195                 200                 205             


Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
    210                 215                 220                 


Ser Leu Ser Leu Ser Pro Gly 
225                 230     


